

Management of hyperthyroidism in adults in India: Consensus statement of the Indian Thyroid Society

ABSTRACT

Hyperthyroidism is a common endocrine disorder characterized by excess circulating thyroid hormones, resulting in multisystem involvement and increased morbidity if inadequately treated. Thyroxine and triiodothyronine play a main role in regulating metabolism, growth, and organ function, and dysregulation of their secretion leads to thyrotoxicosis. Hyperthyroidism may be classified as overt or subclinical based on the biochemical findings. The global prevalence of hyperthyroidism ranges from 0.2% to 1.3%, with Indian studies reporting a prevalence of approximately 0.9%–1.5% in community-based populations. This review summarizes the etiopathogenesis, clinical presentation, diagnostic evaluation, and management of hyperthyroidism, with particular emphasis on evidence from India. Graves' disease is the most common etiology in iodine-sufficient regions, followed by toxic multinodular goiter, toxic adenoma, and thyroiditis. Diagnostic approaches including biochemical testing, thyroid-stimulating hormone receptor antibody assays, thyroid ultrasonography with Doppler, and radionuclide imaging are discussed to facilitate accurate etiological differentiation. Management strategies encompassing symptomatic therapy, antithyroid drugs, radioactive iodine therapy, and surgery are reviewed. The principles of antithyroid drug dosing, titration, duration of therapy, monitoring, treatment-related adverse events, and predictors of remission and relapse are outlined. The review also discusses management considerations in special clinical situations, including acute thyroiditis, thyroid storm, and in women of child-bearing potential, during pregnancy, and lactation. Early recognition and individualized, etiology-based management are essential to prevent complications such as atrial fibrillation, osteoporosis, heart failure, and adverse pregnancy outcomes.

Keywords: Adults, hyperthyroidism, India

INTRODUCTION

Thyroid hormones influence the metabolism, growth, and functioning of all major organ systems. Thyroid hormones include thyroxine (T₄) and triiodothyronine (T₃), which are secreted in a 20:1 ratio, respectively. T₄ is transformed into active T₃, which has three to four times the potency of T₄.^[1]

Hyperthyroidism is a state of thyrotoxicosis due to intrinsic thyroid gland hyperfunction leading to increased synthesis and high circulating thyroid hormone. Thyrotoxicosis is the clinical state as a result of increased thyroid hormones in the body, originating from any cause.^[1]

Based on laboratory results, hyperthyroidism is classified as either subclinical or overt. Reduced serum thyroid-stimulating hormone (TSH) levels and increased levels of total T₃ and/or free T₄ (FT₄) indicate overt hyperthyroidism. Reduced serum TSH levels and normal serum levels of Total T₃ and FT₄ indicate subclinical hyperthyroidism.^[1]

SHASHANK JOSHI, KRISHNA SESHADRI¹, SUJOY GHOSH², PRAMILA KALRA³, ARUN S. MENON⁴, HIMAGIRISH K. RAO⁵, MINI G. PILLAI⁶, SARITA BAJAJ⁷, GANAVI YP⁸, NARENDRA KOTWAL⁹, RAJESH RAJPUT¹⁰

Department of Endocrinology, Joshi Clinic and Lilavati Hospital and Research Centre, Mumbai, Maharashtra, ¹Chennai Diabetes and Endocrine Clinic, Chennai, Tamil Nadu, ²Department of Endocrinology and Metabolism, Institute of Post-Graduate Medical Education and Research, Kolkata, West Bengal, ³Department of Endocrinology, M. S. Ramaiah Medical College, ⁵Clinic of General Surgery, St. Johns Medical College Hospital, Bengaluru, Karnataka, ⁴Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, ⁶Department of Endocrinology, Lakshmi Hospital, Kochi, Ernakulam, Kerala, ⁷Department of Medicine, MLN Medical College, Prayagraj, Uttar Pradesh, ⁸Associate Professor, Department of Endocrinology, M.S. Ramaiah Medical College, Bengaluru, ⁹Director Endocrinology Paras Health, Panchkula, ¹⁰Department of Endocrinology, Pt. B. D. Sharma PGIMS, Rohtak, Haryana, India

Address for correspondence: Dr. Shashank Joshi, Department of Endocrinology, Joshi Clinic and Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India. E-mail: shashanksr@gmail.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License (CC BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Joshi S, Seshadri K, Ghosh S, Kalra P, Menon AS, Rao HK, *et al.* Management of hyperthyroidism in adults in India: Consensus statement of the Indian thyroid society. *Thyroid Res Pract* 2026;22:1-24.

Received: 28-Aug-2025

Revision: 03-Dec-2025

Accepted: 16-Dec-2025

Published: 22-Apr-2026

Access this article online	
Website: https://journals.lww.com/trap	Quick Response Code 
DOI: 10.4103/trp.trp_32_25	

If uncontrolled, hyperthyroidism can result in osteoporosis, congestive heart failure, atrial fibrillation, embolic events, tremors, weakness, and neuropsychiatric symptoms. It can also have a negative impact on pregnancy outcomes and raise death rates.^[2]

Prevalence

Globally, 0.2%–1.3% of the population suffers from hyperthyroidism. In the United States, the prevalence of hyperthyroidism is approximately 1.2% (0.5% overt and 0.7% subclinical).^[3]

In India, the prevalence of hyperthyroidism ranges from 0.9% to 1.5% in people living in the community (not seeking medical attention). In patients attending a hospital for the care of thyroid disorders, the prevalence ranges from 1.79% to 5.3% [Table 1].^[4-11]

Etiopathogenetic causes of thyrotoxicosis [Table 2]^[12]

Excessive TSH receptor stimulation is seen in Graves' hyperthyroidism, human chorionic gonadotropin (hCG)-related thyrotoxicosis, and TSH adenoma. hCG-related thyrotoxicosis includes gestational transient thyrotoxicosis (GTT), familial gestational hyperthyroidism, hydatiform mole, and choriocarcinoma.

Autonomous thyroid hormone secretion is seen in toxic multinodular goiter (MNG) and solitary toxic adenoma, in which thyroid gland nodules secrete excess hormones, independent from TSH or TSH receptor antibodies. Autonomous hormone overproduction can also result from familial or sporadic non-autoimmune hyperthyroidism, which is caused by genetic or environmental causes.

Destructive thyroiditis encompasses subacute de Quervain and silent thyroiditis, postpartum thyroiditis, acute suppurative thyroiditis, and drug-induced thyroiditis. Drug-induced forms include iodide-induced thyrotoxicosis, amiodarone, cytokine, tyrosine kinase inhibitors, and immune checkpoint inhibitors.

Extrathyroidal sources of thyroid hormone include thyrotoxicosis factitia and hamburger thyrotoxicosis, alongside rare occurrences like struma ovarii and metastases of differentiated thyroid cancer.

Out of these, there are four major causes of thyrotoxicosis, which are Graves' disease (GD), MNG, toxic adenoma, and thyroiditis.^[12]

Graves' disease [Table 3]

GD is the most common cause of hyperthyroidism in iodine-sufficient geographic locations. GD is a type of autoimmune

disease characterized by the presence of thyrotropin receptor antibodies (TRABs), also known as thyroid-stimulating hormone receptor (TSHR) autoantibodies, which activate TSH receptors, resulting in excessive thyroid hormone synthesis. Hyperthyroidism is more common in women. Approximately 30% of hyperthyroidism patients have family members who have GD or Hashimoto's thyroiditis. Environmental factors such as smoking, increased iodine intake, stress, and pregnancy can all contribute to hyperthyroidism.^[12] Thyroid ophthalmopathy/orbitopathy, pretibial myxedema (localized fluid-filled and thickened pretibial plaque formation), thyroid acropachy (clubbing of the fingers and toes accompanied by soft-tissue swelling of hands and feet, and periosteal bone growth formation), may be seen in a case of GD.^[13] Diamond's triad in GD refers to a rare combination of exophthalmos, pretibial myxedema, and thyroid acropachy.

Toxic multinodular goiter (Plummer's disease)

A normal thyroid gland usually has a homogenous structure. Follicular cells that are genetically heterogeneous, as well as the acquisition of inheritable qualities in the mother cells, lead to loss of anatomical and functional integrity of the follicles. These factors, when acted on by the elevated TSH as well as external events such as iodine deficiency, goitrogens, inborn errors of thyroid hormone synthesis, and local growth-regulating factors of the tissues, lead to proliferation of the follicle. Growth and fusion of the follicles, which are the structural and functional units of the thyroid glands, may lead to the formation of nodules. A long-standing formation of diffuse and nodular follicles may be detected as a mass in the neck, presenting as a goiter.^[14]

In geographical areas of iodine deficiency, there is a higher prevalence of MNG. It is hypothesized that in iodine-deficient states, the thyroid gland goes through hyperplasia, which is an effect of increased TSH stimulation. When there is iodide repletion or a decreased demand for thyroid hormones, there is an increase in colloid storage, and the thyroid gland enters a resting phase. When cycles of iodine deficiency followed by iodine repletion or decreased demand of thyroid hormones occur, this may result in the formation of the MNG. After several decades of MNG, a large proportion of patients develop hyperthyroidism.^[14]

Iodine deficiency became a recognized national public health concern in India as early as the 1960s. In 1962, the Indian government established the National Goiter Control Programme (NGCP) to identify goiter-endemic zones in the country and supplement the iodine intake of the entire population in these areas. The expansion of NGCP resulted in the determination that all edible salts in India were to be iodized by 1992.^[15]

Toxic MNG (TMNG) is more common in older adults (aged >50 years) compared to GD. Unlike GD, toxic nodular goiter is progressive (except in cases triggered by excessive iodine intake).^[16]

Toxic adenoma

Adenomas in the thyroid gland are non-cancerous tissue growths that could be dormant or active. Active adenomas that produce excessive thyroid hormones are known as toxic thyroid adenomas (TAs).^[17] Toxic adenoma is caused due to somatic activating mutations of genes regulating the growth and thyroid hormone synthesis. It is a single hyper-functioning nodule in the thyroid gland, resulting in localized excess thyroid hormone production. It is characterized by weight loss, palpitations, and heat sensitivity and is commonly found in patients aged 30–60 years.^[12]

Thyroiditis

Thyroiditis is characterized by inflammation of the thyroid tissue, which causes preformed hormones to be released into the bloodstream. Medications, particularly amiodarone, can cause painless thyroiditis. Subacute thyroiditis, which is generally viral in origin, induces thyroid inflammation as well as pain and fever.^[12]

Indian evidence: Prevalence of hyperthyroidism in India

In 2022, a cross-sectional study was conducted by Nijith and Ranjan in South India, including newly diagnosed patients with hyperthyroidism. One hundred forty patients were recruited, of whom 85% were females. The majority of patients had <1 year duration for symptoms. GD was present in 59.3% patients, and MNG was seen in 36.4%.^[18]

In another study in central Kerala by Philip et al.,^[19] patients who had routine health checkups, surgical fitness, or pregnant patients who had an incidental finding of biochemical thyrotoxicosis were included for analysis. Patients in whom symptoms of thyrotoxicosis were present or who were under clinical suspicion of thyrotoxicosis were excluded. Fifty-seven patients were included with an average age of 32.8 years and a female: male ratio of 3.3:1. In these patients, thyroid ultrasound and thyroid scan were undertaken. 91% (n = 52) of patients had subacute thyroiditis (SAT); 47 patients became euthyroid, and 5 became subclinical hypothyroid in 3 months. GD was detected in 9% patients. Authors emphasized that in patients with thyroiditis, it is important to take the wait-and-watch approach instead of starting with antithyroid drugs (ATDs), especially if uptake scans are inaccessible.^[19]

Diagnosis

One of the primary obstacles to the successful treatment of thyroid dysfunction arises from the risk of underrecognition or misinterpretation of these conditions, leading to frequent

instances of misdiagnosis. Hyperthyroidism, in particular, presents a challenge as its diagnosis may be delayed or missed, primarily because its symptoms can manifest across various organ systems, making it easily confounded with other conditions.^[20,21]

Symptoms of hyperthyroidism may also include urinary symptoms, manifesting after 1–6 months after the onset of other symptoms, as voiding abnormalities. Reduced flow rates, increased post-void residual volume, enlarged bladder capacity, and increased perineal muscle electromyographic activity were noted in Goswami et al.^[22] These abnormalities were controlled after return to euthyroidism with carbimazole (CBZ) therapy.^[22]

Neuropsychiatric manifestations in the form of anxiety, dysphoria, emotional lability, mania, psychosis, or a mix of mania and psychosis are also common in hyperthyroidism.^[23,24]

In an Indian study by Goyal et al.,^[25] thyroid function testing in 40 patients presenting with the first episode of mania revealed that 7.5% had hyperthyroidism and 5% had subclinical hyperthyroidism.^[25]

Individuals with suspected or confirmed hyperthyroidism require a thorough evaluation, including a detailed medical history and a comprehensive physical examination. Vital signs such as pulse rate, blood pressure, respiratory rate, and body weight should be assessed. Examination of the thyroid gland for size, tenderness, symmetry, and nodularity is important, along with evaluating pulmonary, cardiac, and neuromuscular function. In addition, the presence or absence of peripheral edema, eye signs, or pretibial myxedema should be noted.^[12,16]

Apathetic hyperthyroidism is a departure from the hyperkinetic clinical presentation of classical hyperthyroidism in that it is characterized by weakness, weight loss, lethargy, depression, and arrhythmia. Since this presentation of hyperthyroidism is commonly seen in the middle-aged and the elderly, the associated signs and symptoms may be mistaken for the natural process of aging. Wu et al.^[26] 2010 determined that decreased free T3 (FT3)/FT4 ratio, increased alanine aminotransferase levels, and bone-specific alkaline phosphatase levels were associated with apathetic hyperthyroidism. FT4 levels were also seen to be significantly higher in the apathetic hyperthyroidism group compared to the classical hyperthyroidism group.^[26]

Indian evidence: Clinical presentation of hyperthyroidism in India

In Nijith and Ranjan's 2022 cross-sectional study, Palpitation was found in 76.4% subjects. With regard to cardiovascular

manifestations, no symptoms were seen in around 20% patients. Heat intolerance was present in 67.9% patients, followed by fatigue (65%) and weight loss 49.3%. Clinical examination revealed tachycardia in 80.7% patients, hypertension in 49.3% and wide pulse pressure in 36.4%. The mean heart rate was 105.8, and the mean pulse pressure was 58.3 mmHg. S1 auscultatory sound was loud in 27.9% of patients, and systolic ejection murmur in the pulmonary area was seen in 17.1% [Table 2].^[18]

If a patient presents with a symmetrically enlarged thyroid, recent onset of orbitopathy characterized by chemosis, proptosis, conjunctival injection, lid lag, exposure keratitis, and extra-ocular muscle dysfunction, and moderate-to-severe hyperthyroidism, GD is likely, and diagnosis may be based on clinical presentation only. Other characteristic symptoms include thyroid acropathy and pretibial myxedema.^[16,27]

Key summary point^[36]

Hyperthyroidism may have a heterogeneous presentation with symptoms manifesting across various organ systems. To avoid delay in diagnosis, which leads to complications, a high degree of clinical suspicion is required. Any person with suspicion of hyperthyroidism must undergo a thyroid function test. TSH <0.01 mIU/L with elevated free T4 and Total T3 are indicative of overt hyperthyroidism

TSH: Thyroid-stimulating hormone

Serology

Thyroid function test

When there is a suspicion of hyperthyroidism in a clinical setting, it is imperative to verify it through biochemical tests, such as observing low TSH levels, elevated FT4, or heightened FT3 levels.

Measuring serum TSH stands out as the most sensitive and specific blood test in assessing suspected thyrotoxicosis, making it the primary screening tool. However, in cases where thyrotoxicosis is strongly suspected, enhancing diagnostic accuracy is achieved by evaluating serum levels of TSH, FT4, and total T3 during the initial assessment.^[16]

In cases of overt hyperthyroidism, serum levels of Total T3, or both, are usually elevated, while serum TSH levels are typically decreased, often falling below 0.01 mIU/L. Notably, due to its higher concentration in the bloodstream, the FT4 assay generally offers greater sensitivity compared to Total T3 assays, which aligns with anticipated results in clinical practice [Table 3].^[16]

The severity of hyperthyroidism can be gauged based on FT4 levels. Baseline T4 levels can also guide the dosing of the antithyroid drugs in the initial stage of management.

Indian evidence: Reference range in India

In 2013 Study conducted in Delhi by Marwaha et al., in 4349 adults between the ages of 18 and 86 years (mean age 41.2 years) with normal thyroid function were recruited. Regardless of the age, the FT4 ranged from 10.1 to 24.8 pmol/L, whereas the FT3 levels ranged from 2.4 to 8.8 pmol/L. The mean TSH value was 2.2 ± 0.9 mIU/L.^[28]

Indian evidence: Role of the free triiodothyronine/free thyroxine ratio

Narkar et al.^[29] remarked on diagnostic assays in India. They argued that although new generation TRAb assays are sensitive and specific for diagnosing GD, these tests are not widely accessible and have cost considerations.^[29] Further, destructive Thyrotoxicosis (DT) is diagnosed with the use of radionuclide scanning. 99mTc-pertechnetate (Technetium-99m sodium pertechnetate) or 131I-iodide (iodine-131 sodium iodide) are commonly used for diagnostic thyroid imaging in India. These investigations are not widely available, contraindicated in pregnancy and lactation, and cannot be used in cases of iodine-containing drugs, food, and contrast.

T3/T4 ratio <20 is suggestive of DT and >20 of GD. Results from Narkar et al.^[29] revealed that in a cohort of 83 patients with overt hyperthyroidism, In patients with GD (n = 22), 74% had T3/T4 ratio >20; in patients with DT (n = 61), 73% had T3/T4 ratio <20. It was determined that T3/T4 ratio had a sensitivity of 73.8%, specificity of 72.7% and diagnostic accuracy of 73.49%.^[29]

It's crucial to identify the underlying cause of thyrotoxicosis. If the diagnosis is not clear from the clinical presentation and initial biochemical assessment, further diagnostic testing is recommended. Depending on the expertise and resources available, this may involve:

- Assessing levels of thyrotropin receptor antibodies (TRAb)
- Examining thyroidal blood flow using thyroid ultrasonography
- Determining radioactive iodine uptake (RAIU)

In cases where clinical signs point towards a TA or a TMNG, obtaining a 123I or 99mTc pertechnetate scan is advisable. These diagnostic steps help to pinpoint the specific etiology of thyrotoxicosis, guiding subsequent treatment decisions effectively.^[16]

TRAb immunoassay [Table 3]

Measurement of TSH receptor antibodies (TRAbs) using competitive binding assays such as TSH-R binding inhibitory immunoglobulin assays, is a sensitive and specific method for diagnosing GD. TRAbs, particularly thyroid-stimulating antibodies (TSAb), are valuable biomarkers for predicting

extrathyroidal manifestations and fetal or neonatal hyperthyroidism.^[30]

Currently, there are two types of TRAb assays available. The Pros and cons are as follows:^[31]

Commercial assays of thyroid antibody testing have predetermined cutoffs for the diagnosis of GD.

TRAb is a sensitive and specific assay for accurate diagnosis and monitoring of GD. Sequential monitoring of TRAb can be used to guide the duration of ATD in GD patients.^[32] Negative or low-titer thyroid receptor antibodies have a high likelihood of remission and can be used as the deciding factor to discontinue ATD treatment.^[33]

TRAb assessment is crucial in pregnant women with suspected GD, history of GD, past treatments like radioactive iodine (RAI) ablation or surgery, or previous instances of fetal thyroid dysfunction. Elevated TRAb levels, especially exceeding three times the upper limit of normal, necessitate close fetal monitoring and neonatal thyroid function assessment during pregnancy. TRAb assessment aids in the differentiation of hyperthyroidism originating from GD versus gestational hyperthyroidism, especially during the early stages of pregnancy. It can determine the necessity for ATDs during the teratogenic period, ensuring the optimal health of both the mother and fetus. Initial TRAb levels should be measured in the first trimester; if elevated, they are measured again at 18–22 weeks of gestation.^[16,30] If maternal TRAb concentration remains high (>3 times the cut off), monitoring of the fetus for thyroid dysfunction throughout pregnancy is recommended.^[34]

TRAbs play a crucial role in the pathogenesis and progression of Graves' ophthalmopathy (GO), serving as specific biomarkers. Measuring functional TRAbs, particularly TSAb, is vital for diagnosing, differentiating, and monitoring GO, which can provide valuable insights for effective disease management.^[35] Patients who are at high risk for deterioration of GO are associated with a high serum TRAb level.

Effect of biotin in thyroid evaluation: Caution must be exerted in patients who are on high-dose (>100 mg/day) biotin supplementation (for hair and nails), which can lead to falsely high T3 and T4 levels and low TSH levels. Biotin may also result in false-positive TRAb levels. Biotin should be stopped for a period of 2–7 days before testing can be employed.^[36]

Indian evidence: Utility of thyroid-stimulating hormone receptor antibodies in India

In a study by John et al.^[19] in Kerala, India, GD was differentiated

from non-GD at presentation with the use of an automated electrochemiluminescence TRAb immunoassay. TRAb tests' sensitivity/specificity of TRAb for diagnosing GD was 98.4%/62.9% at 1.75 IU/L (manufacturer cut off) and 91.2%/90.12% at 3.37 IU/L (study-derived optimal threshold in Indian patients), respectively.^[37]

Imaging

Thyroid ultrasonography

Thyroid Ultrasonography (USG) is a diagnostic modality for assessing hyperthyroid patients that offers swift and non-invasive evaluation without exposing individuals to ionizing radiation. Its utility lies in determining the cause of thyrotoxicosis and identifying thyroid nodules, with the quality of imaging depending on operator expertise and equipment quality, emphasizing the necessity of employing a high-frequency linear probe. GD is often recognized by diffuse thyroid enlargement and hypoechogenicity. Colour-flow or power Doppler examination aids in delineating vascular patterns and quantifying thyroid vascularity. In untreated GD, the thyroid vascularity is increased in multiple small areas, which shows a pulsatile pattern entitled as “thyroid inferno.” Elevated thyroid artery flow velocity and peak systolic velocity (PSV) are seen in untreated GD. The elevated PSV can distinguish GD from SAT or amiodarone-induced thyrotoxicosis type 2, where the blood flow is reduced.

USG findings combined with positive TRAb often obviate the need for scintigraphy, yet the latter remains useful in certain instances, especially before RAI treatment. USG with colour flow Doppler serves as a valuable alternative when RAI is contraindicated, offering insights into thyroid hyperactivity. Despite requiring meticulous adjustments, quantitative Doppler evaluation provides crucial data on thyroid function and pathology through precise measurements of PSV from intrathyroidal arteries, thereby contributing to comprehensive patient management.^[2,16]

Indian evidence: Utility of thyroid USG in India

In a study by Malik et al. in Srinagar, India, to differentiate between 65 patients of GD (n = 46) and thyroiditis (n = 19), the PSV of the inferior thyroid artery (PSV-ITA) using color flow Doppler Ultrasound was compared to technetium-99m pertechnetate thyroid uptake scan. Patients with GD had a higher mean PSV-ITA. A cutoff value of 30 cm/s was shown to have 91 sensitivity and 89% specificity.^[38]

Thyroid scintigraphy

Thyroid uptake Scintigraphy studies is recommended in the case of palpable thyroid nodules or if the etiology is unclear after TRAb testing. This is done using radioiodine uptake or technetium-99m pertechnetate.

RAIU scans show a diffuse uptake in GD, a focal uptake in toxic adenoma or nodules, absent/no uptake in thyroiditis, extra-thyroidal thyroid hormone production, and in high iodine exposure cases.^[36]

In the evaluation of ectopic thyroid tissue and multiple thyroid nodules, Positron Emission Tomography (PET)/single photon emission computed tomography (SPECT)/computed tomography (CT) or PET/SPECT/USG may be an effective diagnostic tool. Tc-99m-methoxy-isobutyl-isonitrile (99mTc-MIBI) may assist in isolating the type of amiodarone-induced thyrotoxicosis.^[39]

18F-fluorodeoxyglucose (18F-FDG) PET scan (18F-FDG-PET/CT scan) may have a role in the diagnosis of autoimmune thyroid disease, such as GD, Hashimoto's thyroiditis, or atrophic autoimmune hypothyroidism. There is an increase in the standardized uptake value in the thyroid parenchyma in these conditions.^[40]

Key summary points^[39]

The etiology of hyperthyroidism must be delineated. TRAb immunoassay is diagnostic for Graves' disease. Radioactive iodine uptake scintigraphy imaging shows differential pictures for Graves' disease, toxic multinodular goiter, toxic adenoma, or thyroiditis. Thyroid USG enhanced with color-flow or power Doppler examination can help identify Graves' disease and thyroiditis

TRAb: Thyroid receptor antibody

Management of Hyperthyroidism

β -blockers offer temporary relief from symptoms of hyperthyroidism; they do not directly address the underlying thyroid dysfunction or its long-term effects. Beta-blockers antagonize the beta-receptor-mediated effects of catecholamines. These medications are commonly employed to regulate blood pressure, alleviate the rapid pulse sensation of palpitations, and reduce tremors and anxiety, since these manifestations are secondary to increased adrenergic activity.^[41]

Role of beta-blockers in initial management [Table 4]

In thyrotoxicosis, there is an increase in the expression of beta-receptors in the heart and other organs. As a result of the hyperadrenergic state due to upregulated beta-adrenergic receptors, there is an increased heart rate, stroke volume, cardiac output, and contractility.^[42,43]

Beta-adrenergic blockade is recommended for managing symptomatic thyrotoxicosis in all patients, particularly targeting elderly individuals and those with resting heart rates exceeding 90 beats per minute or coexisting cardiovascular disease. However, beta-blockers are generally not recommended for patients with bronchospastic asthma.

Alternatively, cardio-selective beta-blockers may be favoured, particularly in patients with asthma, with close monitoring of the pulmonary status. Calcium channel blockers – verapamil (240 mg oral or 5–10 mg intravenous [IV])^[44] and diltiazem (60 mg, orally four times a day)^[45] – can offer rate control in patients who are not candidates for beta-blockers.^[16]

While other β -blockers primarily target hyperthyroidism symptoms, propranolol offers a unique approach with its distinctive dual mechanism of action. The L-isomer of propranolol effectively blocks beta receptors, addressing symptoms like palpitations, anxiety, heat intolerance, and tremors. Meanwhile, the D-isomer inhibits T4 deiodinase, thereby impeding the conversion of T4 to T3 and providing some therapeutic benefit.^[46] In cases where high doses of propranolol (40 mg four times daily) are administered, there is inhibition of peripheral conversion of T4 to T3.^[2]

Beta-blockers are especially beneficial during the early stages before ATDs achieve their maximum therapeutic efficacy. However, beta blockers are only required for the initial symptomatic 6–8 weeks, as they do not appear to alter the synthesis or secretion of the thyroid hormones by the thyroid gland.^[47,48]

Management of Graves' disease

The main goal in the management of GD is to control hyperthyroidism by restoring normal thyroid hormone levels. Additionally, the presence of goiter and/or Graves' ophthalmopathy/orbitopathy (GO) will impact treatment decisions. Patients and physicians have three effective options such as RAI therapy, ATDs, or thyroidectomy.^[16] Surgery or RAI ablates thyroid tissue to control hyperthyroidism, often resulting in hypothyroidism. ATDs, on the other hand, inhibit thyroid hormone synthesis to achieve euthyroidism while preserving the thyroid gland.^[69]

Medical management

ATDs represent the mainstay of therapy in most regions, including Europe, Asia, and the United States. It serves as the first-line treatment for GD, particularly in younger patients with mild or uncomplicated disease. ATDs include thionamides, such as CBZ, methimazole (MMI), and propylthiouracil (PTU). These medications work by interfering with the function of thyroperoxidase, an enzyme crucial for iodide organification within the thyroid gland and inhibiting the coupling of iodotyrosines, thereby reducing the production of thyroid hormones.^[2]

Studies have shown that ATDs not only decrease thyroid hormone levels but also reduce TRAbs, a hallmark of GD, which are responsible for the stimulation of the thyroid

gland. Therefore, ATDs enhance remission rates compared to no treatment.^[2]

CBZ is the preferred first-line ATD in non-pregnant individuals. CBZ has been available in India since 1963.^[49] The Indian National List of Essential Medicines includes CBZ (5 mg and 10 mg) for wider accessibility, even at the primary healthcare level.^[50] CBZ offers a dose finer titration compared to MMI (Carbimazole doses of 60 mg, 45 mg, 40 mg, 30 mg, 25 mg, 20 mg, 15 mg, 10 mg and 5 mg have a Calculated active metabolite of 36 mg, 27 mg, 24 mg, 18 mg, 15 mg, 12 mg, 9 mg, 6 mg, and 3 mg which offers finer titration than methimazole [multiples of 5 mg and 10 mg]). This is an added advantage in the treatment of hyperthyroidism, where carefully dose-optimized treatment is required according to each patient's thyroid biomarkers. CBZ may even result in fewer cases of iatrogenic hypothyroidism and use of concomitant supplemental T4 (In Baek *et al.*,^[69] one of the main reasons for the change in ATD from methimazole to carbimazole was for further reduction in ATD dose. Carbimazole [$n = 38$] with a mean dose of 2.3 mg [at the time of stopping of ATD] for a duration of 36 months, compared to methimazole [$n = 166$] with mean dose of 3 mg for a duration of 30 months, decreased the risk of relapse [Hazard Ratio 0.248, $P = 0.004$]).^[69]

While the mechanism of action of PTU is similar to that of CBZ and MMI, it offers an additional benefit when given in higher doses. It acts by inhibiting the peripheral conversion of T4 (T4) to the more potent T3. However, this effect is considered marginally beneficial except in cases of severe thyrotoxicosis. Furthermore, the shorter half-life of PTU compared to CBZ and MMI makes it less practical for long-term management.^[2]

Dosing, titration, and duration^[51]

Dosing

The initial dose of CBZ or MMI should be adjusted according to the severity of hyperthyroidism, and it should be roughly estimated based on the baseline levels of FT4 hormone.^[52]

Rationale for initial dose

The reason behind determining the initial dose is rooted in how these medications work in the body, for example, in the case of CBZ, it rapidly converts to MMI, which tends to concentrate in the thyroid gland. MMI normally stays in the thyroid for about 20 h. Starting with higher doses can help bring the disease under control faster, especially in cases where quick stabilization is necessary.^[54,55]

Single dose regimen for carbimazole

The antithyroid effects of CBZ and MMI are associated with their intrathyroidal actions, where they remain in high

concentrations for up to 20 h. Single-dose CBZ in a dose of 30 mg has been shown to be efficacious in the initial treatment of hyperthyroid GD patients with attainment of clinical euthyroidism and normalization of serum T4 levels within 1–3 months. A single-daily dose of 30 mg in the initial regimen instead of multiple doses is convenient and can improve patient compliance.^[56,57]

Indian evidence: Carbimazole in Indian patients

In a 1992 Indian study by Gupta and Godbole^[57] in an area of mild iodine deficiency, patients administered a single daily dose of 30 mg CBZ ($n = 19$) were compared with 10 mg CBZ every 8 h ($n = 14$). Total T4, Total T3, and TSH were estimated at baseline and at 1, 2, 3, 4, and 6 after treatment. Duration to euthyroidism was found to be similar in 30 mg OD (4.6 weeks) and 10 mg TID group (3.8 weeks) ($P > 0.05$). Therefore, a single daily dose of CBZ is comparable to multiple daily dose.^[57]

Titration

After initiation of the treatment, thyroid function tests are often reviewed 3–4 weeks later to titrate the dose based on FT4 and total T3 levels. A significant proportion of patients achieve euthyroidism within this period. TSH levels often remain suppressed for several months and therefore do not provide a sensitive index of early treatment response.^[2]

The titration regimen is often preferred where the dose is minimized in accordance with the cascading TFT results. CBZ is initially dosed at 10–40 mg daily and titrated until maintenance of 5–15 mg is achieved.^[58,59] As antithyroid therapy is initiated, thyroid hormone secretion decreases, and the drug dose should be decreased to avoid hypothyroidism.^[20]

In Yap, after euthyroidism was achieved with a single daily dose of CBZ in 24 patients, the maintenance phase of treatment was initiated. A single daily dose of 15 mg CBZ was seen to be as effective as conventional doses of 5 mg thrice daily.^[59]

Lowering the medication dosage without causing thyrotoxicosis to worsen indicates a reduction in disease activity. This may be due to a decrease in the production of TSH receptor autoantibodies (TRAb). In addition, the treatment goal shifts from complete inhibition of T4 and T3 synthesis to only partial inhibition.^[20]

TSH remains suppressed for the first 6 months of treatment and therefore is an unreliable biomarker for early response to ATD treatment.^[60]

Certain factors can predict a low remission rate before beginning the treatment of thyroid-related conditions. These predictors include a large goiter, Graves' ophthalmopathy/

orbitopathy (GO), high thyroglobulin levels, high levels of TRAb, and pretibial myxedema [Table 7].^[52]

During the treatment, several factors can indicate poor responsiveness, such as persistently low TSH levels or high TSHR autoantibody (TRAb) levels. The duration of elevated TRAb can vary from patient to patient. Although the recommended treatment length is typically more than 1 year, persistently high TRAb levels beyond this period are the most useful predictor of a low remission rate [Table 7].^[52]

Rationale for 12–18 months' duration

ATD therapy often leads to the normalization of TRAb levels over time in many patients, which plays a significant role in achieving remission after long-term treatment.^[2,53,54]

- TRAb titers typically decrease during ATD therapy and resolve in 70%–80% of patients within 18 months of treatment
- Reported remission rates, defined as achieving euthyroidism 1 year after discontinuing treatment, are around 50%–55% after an initial 12–18 months of ATD therapy
- However, if the patient continues to test positive for TRAb, the likelihood of remission is much lower, ranging from 0% to 20%.

According to McGregor et al.,^[61] the use of CBZ in patients with mild GD resulted in the inhibition of TRAb.^[61] The study demonstrated that CBZ directly impacted the autoantibody levels independent of its action on serum T4, which helped control hyperthyroidism. During the initial stages of CBZ treatment, both autoantibody levels and thyroid hormone levels decreased. However, after 6 weeks, when thyroid hormone levels were maintained within the normal range with CBZ and the use of T4 supplements, autoantibody levels continued to decrease over time.^[61]

In Morales García et al.,^[62] patients who achieved euthyroid status at 10–12 months with low doses of ATDs were evaluated. In the group of patients where ATDs (CBZ or MMI: 2.5–5 mg/day) in low doses were continued for a period of 5 years (N = 53; CBZ [N = 50]; MMI [N = 3]), the relapse rate was 22.64%. In the group that did not continue ATD after reaching euthyroidism at 10–12 months (N = 31), the relapse rate was 77.42% (P < 0.000).^[62]

In Azizi et al.,^[63] the efficacy of prolonged ATD administration in GD was investigated. The findings revealed that after a 5-year regimen of MMI therapy, a persistent normalization of TSH receptor antibodies (TRAb) was observed. Furthermore, the study noted that ATD treatment extending beyond 60 months yielded a remission rate of 85% over 4 years. The research concluded that long-term ATD therapy (for at least 60 months) exhibited both

safety and effectiveness, highest remission rates and often leading to the complete resolution of GD symptoms in most patients.^[63,64]

In a systematic review and meta-analysis by Azizi and Malboosbaf,^[65] integrated findings from six studies with outcomes from long-term (>24 months) ATD treatment were analyzed. The annual remission rate for each year of treatment was found to be 16% (confidence interval [CI] 10%–27%), showing a slightly higher rate in adults compared to non-adults (19% vs. 14%). In addition, long-term ATD treatment exceeding 24 months induced a remission rate of 57% (CI 45%–68%), showing a similar trend of higher rates in adults than in nonadults (61% vs. 53%). The complication rate was found to be 19.1% (CI 9.6%–30.9%). Major complications accounted for 1.5% of the total complications observed.^[65]

Low-dose antithyroid drug [Tables 6 and 8]

An important aspect of the medical management of patients with GD and Graves' Ophthalmopathy includes prevention of iatrogenic hypothyroidism.^[66,72-75] This may be achieved by reducing the antithyroid medications to a minimum of 2.5 mg during the maintenance phase.^[66] Furthermore, some people are extremely sensitive to low doses; therefore, even 2.5–5 mg CBZ/day may be required to maintain control.^[67]

Block and replace

The “block and replace” therapy is an alternative to titration-based monotherapy. Upon achievement of euthyroidism, using CBZ (dosage 30–40 mg once daily), T4 replacement therapy (100–125 µg daily) is initiated. This is to prevent iatrogenic hypothyroidism and reduce the frequency of biochemical tests. Treatment may last 6 months, or it may be extended, particularly in the presence of significant thyroid eye disease (TED). Some clinicians use this strategy in case of alterations in thyroid function throughout the treatment.^[58]

Patients with Graves' Alternans, who alternate between hyperthyroidism and hypothyroidism status, may have TSHR blocking autoantibodies that fluctuate over time, which can be difficult to manage clinically. In such cases, the “block and replace” strategy can be beneficial in delivering both ATDs and levothyroxine parallelly.^[52]

Biochemical goal of treatment

During every visit of follow-up, the dose of the antithyroid drug must be titrated and adjusted according to the FT4 and T3 levels. The serum concentration of the FT4 and T3 should be targeted to the middle range of normal values in nonpregnant adults with hyperthyroidism. Further, once the TSH has been normalized, it should be maintained within the reference range.^[71]

Follow-up^[2,16]

Adults using antithyroid medications for hyperthyroidism should consider:

- Assessment of FT4 and total T3 levels 2–6 weeks after starting therapy to determine the severity of thyrotoxicosis and alter drug dosage accordingly
- Monitoring of serum T3 levels should also be done as FT4 levels may normalize despite persistent elevated serum total T3 levels
- Monitoring of TSH, FT4, and FT3 levels every 6 weeks until TSH is normalized
- Monitoring of TSH (with cascading) every 3 months until antithyroid medications are discontinued
- For patients undergoing long-term ATD (> 18 months), the interval can be extended to 6 months
- For patients who have stopped ATD, consider routine monitoring with
 - TSH: Within 2 months of stopping ATD, then
 - TSH every 3 months for 1 year, then
 - TSH once a year.

Adverse events and when to expect [Table 9]^[66,72-76]

ATD therapy is definitively contraindicated in case of known significant adverse effects in the past.

Monitoring for adverse events:^[2,16,51]

- Unless there is a suspicion of agranulocytosis or liver dysfunction, there is no requirement to routinely monitor the complete blood count and the liver function in patients who are on ATDs
- Patients need written instructions regarding the identification of symptoms of possible agranulocytosis, which include sore throat, mouth ulcers, fever, and the cessation of ATD treatment pending a differential white blood cell (WBC) count.^[66,72-76]

Medical treatment outcomes**Remission [Tables 5 and 8]^[146]**

A patient is considered to be in the remission stage if they have had normal blood TSH, FT4, and total T3 for 1 year after discontinuing ATD therapy. Maximum remission rates (50%–55%) are attained between 12 and 18 months.

TRAb levels should be measured before discontinuing ATD therapy because they help predict which individuals can be weaned off the medicine, with normal levels indicating a higher possibility of remission. Patients with consistently high TRAb levels after 12–18 months can continue CBZ/MMI medication and retake the TRAb test after another 12 months, or they can have RAI or thyroidectomy.

Relapse/recurrence after a course of antithyroid drug^[2]

Relapse is most frequent in the first 6–12 months after ATD cessation, but it can happen years later. Patients with severe hyperthyroidism, big goiters, or persistently high TRAb levels are more prone to relapse when medication is discontinued, although the prognosis is unpredictable. All patients should be thoroughly monitored for relapse during the 1st year after treatment, and at least once a year thereafter.

In patients who are contraindicated for antithyroid treatment, RAI and surgery options can be explored.

Radioiodine therapy in Graves' disease

Candidates for RAI are Women planning a pregnancy in the future (in >6 months following RAI administration, provided thyroid hormone levels are normal), individuals with comorbidities increasing surgical risk, patients with previously operated or externally irradiated necks, lack of access to a high-volume thyroid surgeon, patients with contraindications to ATD use or failure to achieve euthyroidism during treatment with ATDs, patients with periodic thyrotoxic hypokalemic paralysis, right heart failure pulmonary hypertension, or congestive heart failure.^[16]

Radioiodine therapy stands as the definitive treatment of choice for many countries, particularly for patients with small goiters (<50 g) or those with challenges in managing their condition with thionamides or facing contraindications to such drugs. The overarching therapeutic goal of GD is the induction of hypothyroidism in affected patients. This treatment effectively resolves hyperthyroidism in over 90% of patients afflicted with GD or autonomous thyroid nodules.^[36,52]

However, several factors have been identified that may contribute to persistent hyperthyroidism following RAI treatment for GD. These include male gender, prior ATD therapy, prolonged treatment duration exceeding 6 months after diagnosis, elevated levels of FT4, larger thyroid volume, and heightened RAIU. Notably, achieving a euthyroid state before radioiodine therapy is recommended to mitigate the risk of radiation-associated thyroiditis, which can exacerbate thyroid hormone levels.^[36,52]

For older patients and individuals with increased cardiovascular risk, it is recommended to administer β -blockers and initiate pretreatment with CBZ or MMI to mitigate the transient exacerbation of hyperthyroidism following radioiodine therapy. For this regimen, CBZ or MMI administration should be discontinued 2–7 days before treatment and may be resumed 3–7 days afterward. Radioactive sodium iodide (Na¹³¹I) is

administered orally and promptly accumulates in the thyroid gland. Subsequently, it induces significant tissue damage, resulting in the ablation of the thyroid gland and subsequent reduction in thyroid hormone levels within a period of 6–18 weeks. The dosage of ^{131}I may either be standardized (e.g., 10 mCi or 370 MBq) or tailored based on the size of the goiter and the uptake of radioiodine. Following the attainment of hypothyroidism, initiation of thyroid hormone replacement therapy is warranted.^[12,36,52]

Radioiodine treatment is contraindicated during pregnancy, lactation, and in patients with Graves' orbitopathy due to its potential to exacerbate the condition. Smokers are at an increased risk of Graves' orbitopathy and are also advised against radioiodine therapy. Moreover, radioiodine therapy may exacerbate or induce eye disease in patients with GD, particularly those who smoke or have high TRAb levels. To mitigate this risk, pretreatment with prednisone, tapered over 3 months, is recommended for smokers, individuals with elevated TRAb levels, or those with preexisting TED.^[36,52]

Monitoring of radioactive iodine treatment^[51]

Following RAI treatment, it is recommended to monitor thyroid function in adults closely by measuring TSH, FT4, and FT3 levels, every 6 weeks for the initial 6 months until TSH levels are normalized. In adults who develop hypothyroidism post-treatment and are not taking ATDs, levothyroxine replacement therapy should be initiated. The starting dosage varies based on age and cardiovascular history. Adults aged <65 years with primary hypothyroidism and no history of cardiovascular disease may be given levothyroxine (1.6 µg/kg body weight/day), rounded to the nearest 25 µg. Conversely, for adults aged ≥65 years or those with a history of cardiovascular disease, levothyroxine (lower dosage of 25–50 µg/day) with titration is advised. While treating primary hypothyroidism with levothyroxine, the goal is to maintain TSH levels within the reference range. If symptoms persist, adjusting the dose of levothyroxine further may be necessary to achieve optimal well-being. However, caution should be exercised to avoid doses that cause TSH suppression or thyrotoxicosis.

It is important to note that it can take up to 6 months for TSH levels to return to the reference range, especially in individuals with very high initial TSH levels or a prolonged period of untreated hypothyroidism. Therefore, adjustments to the levothyroxine dose should consider this duration.

For adults with TSH levels within the reference range, 6 months after RAI treatment, consider measuring TSH at 9 and 12 months after treatment. If TSH levels remain within the reference range 12 months following treatment, these

should be monitored every 6 months unless hypothyroidism develops. In cases where hyperthyroidism persists after RAI treatment, consider using ATDs until the 6-month visit. If hyperthyroidism is present after 6 months of treatment, further treatment choices should be explored.

Surgery

Candidates for surgery in the management for GD include women planning a pregnancy in <6 months provided thyroid hormone levels are normal, symptomatic compression or large goiters (≥80 g); low uptake of RAI; when thyroid malignancy is documented or suspected, large thyroid nodules especially if >4 cm or if nonfunctioning, or hypofunctioning on ^{123}I or $^{99\text{m}}\text{Tc}$ pertechnetate scanning; coexisting hyperparathyroidism requiring surgery especially if TRAb levels are particularly high; moderate to severe active Graves ophthalmopathy [Table 5].^[16]

Surgery (thyroidectomy) offers a definitive option for some patients of GD. Thyroidectomy ensures a swift return to a euthyroid state but carries a low risk of complications (around 1%–2%) like bleeding, infection, or recurrent laryngeal nerve damage affecting the voice.^[12] Complications are fewer if thyroidectomy is performed by experienced surgeons.^[12] Total thyroidectomy is the preferred surgical approach for GD because it minimizes the chance of hyperthyroidism recurring compared to a subtotal thyroidectomy. However, this procedure necessitates lifelong thyroid hormone replacement therapy to compensate for the absence of thyroid gland function. In preparation for surgery, patients are brought to a euthyroid state with ATDs and also β-blockers are used to control cardiac rhythm. In addition, vitamin D and calcium supplementation may be given to prevent postoperative hypocalcemia, especially in patients who are at high risk of parathyroid injury.^[52] Following thyroidectomy, thyroid hormone replacement therapy is initiated to manage the hypothyroid state, with serum TSH levels monitored every 4–6 weeks postoperatively to adjust dosing as needed.^[52]

Key summary points^[44,45,47,48]

In cases of symptomatic thyrotoxicosis, it is necessary to initiate beta-blockers (unless contraindicated in which case calcium channel blockers are recommended), especially in patients with comorbidities. Beta-blockers are recommended in the initial symptomatic thyrotoxic phase for a period of 6–8 weeks

Propanolol in doses of 10–40 mg given in a frequency of 3–4 times per day is recommended

In diagnosed patients with Graves' disease, the first line of therapy is antithyroid drugs. Carbimazole is the preferred antithyroid drug in India in nonpregnant hyperthyroidism patient

In patients with Graves' disease, the titration regimen is preferred over the block and replace regimen for most cases. The initial dose is determined based on the free T4 levels and leads to normalization of free T4 within 4–6 weeks. From the initial dose, the dose is serially downtitrated to the lowest maintenance dose, depending on the cascading thyroid function tests every 6 weeks–3 months

Contd...

The lowest maintenance dose of carbimazole may be in the range of 2.5–10 mg [Table 8]

In Graves' disease, during follow-up in titration regimen, dose of antithyroid drug must be titrated and adjusted according to free T4 and Total T3 levels. The serum concentration of the free T4 and Total T3 should be targeted to the middle range of normal values. TSH is an unreliable biomarker for early response of the ATD treatment. Once the TSH normalizes, it should be maintained within the reference range

Antithyroid drugs must be continued for a period of 12–18 months for achieving a maximum remission rate of 50%–55%. Review for continuation of carbimazole must be undertaken after 12–18 months of treatment

Antithyroid drugs may be given for more than 5 years in a low maintenance dose. Long-term ATD has led to a remission rate of 85% with a good safety profile. For patients undergoing long-term treatment with ATD (>18 months), the follow-up interval can be 6 months

For patients who have stopped ATD treatment, consider routine monitoring with TSH within 2 months of stopping ATD, then every 3 months for 1 year, and then annually

ATD therapy is contraindicated in case of known significant adverse effects in the past

A baseline complete blood count, including white blood cell count and differential count, and liver function test must be done before initiating ATD

Patients need written instructions regarding the identification of symptoms of possible agranulocytosis, which include sore throat, mouth ulcers, fever, and the cessation of ATD treatment pending a differential white blood cell count

Unless there is a suspicion of agranulocytosis or liver dysfunction, there is no requirement to routinely monitor the complete blood count and the liver function in patients who are on antithyroid drugs

In patients requiring RAI treatment, it is recommended to administer beta-blockers and initiate pretreatment with antithyroid drugs to mitigate the transient exacerbation of hyperthyroidism following radioiodine therapy. For this regimen, carbimazole or methimazole administration should be discontinued 2–7 days before treatment and may be resumed 3–7 days afterward

The dosage of ¹³¹I may either be standardized (e.g., 10 mCi or 370 MBq) or tailored based on the size of the goiter and the uptake of radioiodine. Following the attainment of hypothyroidism, initiation of thyroid hormone replacement therapy is warranted

Radioiodine treatment is contraindicated during pregnancy, lactation, and in patients with Graves' orbitopathy due to its potential to exacerbate the condition. Smokers are at an increased risk of Graves' orbitopathy, and are also advised against radioiodine therapy

Following radioactive iodine treatment, it is recommended to monitor thyroid function in adults closely by measuring TSH, FT4, and FT3 levels, every 6 weeks for the initial 6 months until TSH levels are normalized

Total thyroidectomy is the preferred surgical approach for GD because it minimizes the chance of hyperthyroidism recurring compared to a subtotal thyroidectomy. Complications are fewer if thyroidectomy is performed by experienced surgeons. In preparation for surgery, patients are brought to a euthyroid state with antithyroid drugs and β -blockers

RAI: Radioactive iodine, TSH: Thyroid-stimulating hormone, GD: Graves' disease, ATD: Antithyroid drug, FT4: Free thyroxine, FT3: Free tri-iodothyronine

Graves' ophthalmopathy/orbitopathy

Graves' ophthalmopathy/orbitopathy (GO), also known as TED or thyroid-associated orbitopathy, is an inflammatory autoimmune illness that affects about 25% of GD patients. GO primarily affects young women. It typically begins between the third and fourth decades of life, and its clinical manifestation may be more severe in senior persons and men, and milder in the Asian population. Mild and nonprogressive cases are more common, whereas moderate-to-severe forms account for only 5%–6%.^[66,72-75] Although GO is self-limiting

in the majority of patients, it can be profoundly disabling due to its impact on vision and appearance, resulting in a considerable loss in quality of life.^[77]

Indian evidence: Graves' orbitopathy in India

Reddy et al.^[78] conducted a study in the referral center of North India. The study reported a Graves' ophthalmopathy prevalence of 28% (65 patients) among 235 newly referred patients with GD with a similar distribution between males (28%) and females (27%). The condition was mild in 83%, moderate-severe in 15%, and sight-threatening in 2% of patients, and only two (3%) instances had active ophthalmopathy. The most common presentation was upper eyelid retraction (83%), followed by exophthalmos (75%).

Management of Graves' ophthalmopathy/orbitopathy^[66,72-75]

The choice of treatment for Graves' ophthalmopathy/orbitopathy is determined based on the clinical activity, severity, and disease duration, since anti-inflammatory or immunosuppressive treatments are less effective after 18 months of disease duration.

Patients at risk of deterioration, including clinically active Graves' ophthalmopathy/orbitopathy, smokers, severe/unstable hyperthyroidism, and high serum thyrotropin receptor antibody (TRAb) titers, must be referred to combined thyroid-eye clinics or specialized centres with endocrine and ophthalmic expertise for an accurate and timely diagnosis to improve prognosis and quality of life. All patients with Graves' hyperthyroidism, regardless of the presence or absence of Graves' ophthalmopathy/orbitopathy should be encouraged to avoid smoking. Counselling and therapy options for moderate to severe, active Graves' ophthalmopathy/orbitopathy (GO) should be discussed with the patients.

Medical management

1. Comparison of different treatment modalities for mild, moderate-severe, and severe Graves' ophthalmopathy/orbitopathy
 - **Mild Graves' ophthalmopathy/orbitopathy^[72]**
Mild GO should be treated with local treatments and risk factor control measures. Mild and inactive GO can be treated based on the patient's preference, along with the standardized criteria. Patients with mild and active GO of recent onset should receive a 6-month selenium supplementation to improve eye-related manifestations and quality of life and prevent progression to more severe forms. Treatment with ATDs or thyroidectomy is recommended for hyperthyroidism; prophylactic treatment with prednisone/prednisolone may be considered only in patients undergoing RAI.

- **Moderate to severe Graves' ophthalmopathy/orbitopathy^[72]**

Mycophenolate sodium (or mofetil) is the primary treatment for moderate-to-severe and active GO. For moderate-to-severe and active GO, including constant and inconstant diplopia, severe inflammatory signs, and exophthalmos >25 mm, IV methyl-prednisolone at the highest cumulative dose (7.5 g per cycle) as monotherapy is a valid first-line treatment.

A 1-year follow-up study of previously untreated patients with moderate-severe GO demonstrated that although a low dose of prednisolone was well tolerated, IV pulse methylprednisolone (0.5 g given thrice a month for 4 months) was more effective compared to oral prednisolone 1 mg/kg/day for 6 weeks.^[79]

If primary treatment fails and there is no improvement in the severity of GO, second-line treatments after evaluating ocular and biochemical factors (liver enzymes) such as IV methylprednisolone monotherapy with high single doses (0.75 g) and a maximum cumulative dose of 8 g each cycle, oral prednisolone or prednisolone in combination with cyclosporine or azathioprine, orbital radiotherapy combined with oral or IV glucocorticoids, azathioprine rituximab, or tocilizumab are recommended for moderate-to-severe and active GO. Prednisone or prednisolone prophylaxis should be used if RAI treatment is chosen and in the presence of risk factors such as smoking and high TRAb.^[72]

Li *et al.*^[80] performed a network meta-analysis to identify 15 trials in an attempt to compare the effects of various treatment modalities on active, moderate-to-severe GO. IV glucocorticosteroids at low (4.5–5 g), moderate (6 g), and high (7–8 g) cumulative dosages outperformed oral glucocorticosteroids in improving the overall response rate. They further validated that the cumulative low dose (4.5–5 g) was the most appropriate regimen during the evaluation of efficacy and safety outcomes. An average IV glucocorticoid dose of 3.8 g was reported by an Indian study by Gupta *et al.*^[81] that investigated visual morbidity in patients with GO.^[81]

Another meta-analysis consisting of 12 trials and 448 patients, suggested that tocilizumab provided a significant reduction in proptosis and was a safe drug of choice, followed by rituximab.^[82]

For moderate-to-severe and active GO, ATDs should be used to manage hyperthyroidism until the treatment for GO treatment is completed.

- **Sight-threatening Graves' ophthalmopathy/orbitopathy^[72]**

High doses of IV methylprednisolone (0.5–1 g daily for 3 days or every second day) should be administered immediately in patients with optic neuropathy. In case of a lack of improvement within 1–2 weeks, urgent orbital decompression should be performed. Further patients with recently developed ocular subluxation should also undergo orbital decompression on an urgent basis. Severe corneal exposure should be rapidly treated medically or with more intrusive procedures to minimize progression to corneal breakdown, which should be surgically corrected immediately.

Due to the serious nature of the disease, treating GO should be prioritized while ATDs can be used to control hyperthyroidism during this period. ATD treatment given in the long term is beneficial in patients with GO due to decline in the serum TRAb levels as well as normalization of the thyroid function. Caution must be undertaken to avoid hypothyroidism of iatrogenic cause in such patients.^[72]

Key summary points^[66,72-75]

Patients at risk of deterioration, including clinically active GO, smokers, severe/unstable hyperthyroidism, and high serum TRAb titers, must be referred to combined thyroid-eye clinics or specialized centers with endocrine and ophthalmic expertise for an accurate and timely diagnosis to improve prognosis and quality of life

Due to the serious nature of the disease, treating GO should be prioritized, while ATDs can be used to control hyperthyroidism during this period. ATD treatment given in the long term is beneficial in patients with GO due to a decline in the serum TRAb levels as well as normalization of the thyroid function

Patients with mild and active GO of recent onset should receive a 6-month selenium supplementation to improve eye-related manifestations and quality of life and prevent progression to more severe forms. Treatment with ATDs or thyroidectomy is recommended for hyperthyroidism

Mycophenolate sodium (or mofetil) is the primary treatment for moderate-to-severe and active GO. For moderate-to-severe and active GO, including constant and inconstant diplopia, severe inflammatory signs, and exophthalmos >25 mm, IV methylprednisolone at the highest cumulative dose (7.5 g per cycle) as monotherapy is a valid first-line treatment

High doses of IV methylprednisolone (0.5–1 g daily for 3 days or every second day) should be administered immediately in patients with optic neuropathy. In case of a lack of improvement within 1–2 weeks, urgent orbital decompression should be performed. Further, patients with recently developed ocular subluxation should also undergo orbital decompression on an urgent basis. Severe corneal exposure should be rapidly treated medically or with more intrusive procedures to minimize progression to corneal breakdown, which should be surgically corrected immediately

TRAb: Thyrotropin receptor antibody, ATDs: Antithyroid drugs, IV: Intravenous, GO: Graves' ophthalmopathy

Multinodular goiter

Multi-nodular goiter is prevalent in areas where there is a prevalence of mild to moderate iodine deficiency. It is more

frequently observed in women and typically manifests during the fourth and fifth decades of life.^[83]

Diagnosis and assessment^[16,51]

MNG can be characterized by subclinical hyperthyroidism for a long duration, which precedes the development of clinical signs and symptoms. The clinical signs associated with MNG are milder compared to GD. Arrhythmia and atrial fibrillation are commonly associated with multinodular goiter. Thyroid scintigraphy scans are useful for assessing thyroid nodularity, showing an uneven radionuclide distribution of numerous hyperfunctioning and cold nodules in TMNGs. USG can help identify the size and number of nodules, whereas the colour Doppler can give an estimate of the vascularity. To exclude malignancy in the cold nodules, fine needle aspiration cytology may be indicated. CT and magnetic resonance imaging may help to delineate retrosternal and recurrent enlargement of the thyroid gland.

Management Recommendations^[16,51]

Symptomatic treatment

Beta-adrenergic blockade is recommended in all symptomatic thyrotoxicosis patients, particularly those with resting heart rates over 90 bpm or coexisting cardiovascular disease. Caution is advised in patients with bronchospastic asthma, where beta-blockers are generally contraindicated; alternatively, relative beta-1 selective agents can be used with careful monitoring. Calcium channel blockers like verapamil (240 mg oral or 5–10 mg IV)^[44] or diltiazem (60 mg, orally four times a day)^[45] can be administered for rate control in patients intolerant to or unsuitable for beta-blockers.

Beta-blockers in asymptomatic patients who are at a high risk for complications is required if radioiodine is the mode of treatment. This is because the RAI may lead to a transient worsening of hyperthyroidism in patients with TMNG or TA.

Treatment for multinodular goiter

For TMNG, treatment options include RAI, thyroidectomy, or low-dose MMI in some cases. RAI and surgery swiftly eliminate hyperthyroidism, with RAI achieving 50%–80% response rates in TMNG and surgery resulting in prompt euthyroidism in TA. Factors guiding treatment selection include age, comorbidities, goiter size, and patient preference. RAI is preferred in patients with older patients, prior surgery or scarring in the anterior neck, small goiter size, lack of access to surgery, and a RAIU that is sufficient to allow therapy. Contraindications to RAI include pregnancy or women planning pregnancy within 6 months, lactation, coexisting thyroid cancer, and patients who will not be able to follow the radiation safety guidelines.

Prior to RAI, pre-treatment with beta-blockers and ATD must be given to prevent complications. Sufficient RAI in a single

dose should be administered to alleviate hyperthyroidism in TMNG. Follow-up for thyroid function test (FT4, total T3, and TSH) is evaluated after the RAI is within 1–2 months of treatment. Thereafter, biochemical monitoring is at every 4–6 week intervals for 6 months. If the patient becomes hypothyroid, monitoring is continued till the patient stabilizes on thyroid hormone supplementation. If hyperthyroidism persists after 6 months, retreatment with RAI is suggested.

Surgery by a high-volume surgeon is preferred in patients who have compressive symptoms or signs, coexisting thyroid cancer concern. Coexisting hyperparathyroidism that requires surgery, a large goiter size (>80 g), retrosternal or substernal extension, and immediate hyperthyroidism resolution. Surgery is not recommended in certain comorbidities, such as cardiopulmonary disease, debilitating disorders such as cancer, and lack of access to a high-volume surgeon. In pregnancy, surgery must be considered only if the patient is uncontrolled on ATD or rapid control is required.

If surgery is the chosen modality of treatment, pretreatment with ATD is required for achieving euthyroidism. Beta-blockers in surgery are required in symptomatic patients as well as patients at risk of complications. Beta-blockers can be slowly discontinued following the surgery. Near-total or total thyroidectomy is the preferred surgical approach. Post-thyroidectomy, serum calcium with or without iPTH levels should be measured. Based on the measured levels, oral calcium and calcitriol supplementation may be needed.

After thyroidectomy, thyroid hormone supplementation must be initiated with TSH measured every 1–2 months until the patient is stable. Monitoring must be continued annually thereafter. In case of persistence of hyperthyroidism, RAI should be used for retreatment. For select patients in whom RAI or surgery are not feasible, alternative therapies such as ethanol or radiofrequency ablation may be considered, provided expertise in these procedures is available.

Long-term antithyroid drug^[84]

A clinical study compared the effectiveness of long-term MMI (LT-MMI) versus RAI treatment in managing hyperthyroidism in patients with TMNG. The study demonstrated that LT-MMI therapy led to earlier attainment of euthyroidism and longer sustained normal serum thyrotropin levels compared to RAI treatment. In addition, no major treatment-related adverse events were observed in either group.

Toxic adenoma

TAs are noncancerous growths found in the thyroid gland. While some are dormant, others produce thyroid hormones. When they are hormonally active, they are known as toxic TAs.^[85]

Diagnosis and assessment^[16,51,86]

TAs are sporadic in nature and occur more in females. TAs are associated with iodine deficiency. Around 1% of patients with TA have hyperthyroid symptoms. Commonly, TA patients are asymptomatic, may have a visible or palpable thyroid mass, and rarely have dyspnea, dysphagia, and hoarseness of voice. Thyroid function tests, thyroid ultrasound (to distinguish adenoma from carcinoma-carcinoma may be identified by irregular margins, microcalcifications, hypoechogenicity, absent halo sign, and increased intranodular blood flow), fine needle aspiration biopsy (for adenoma with high suspicion of malignancy), iodine-123 (to distinguish between a hyperfunctioning and a hypofunctioning nodule) and genetic evaluation in some cases may be required for diagnostic evaluation.

Management recommendations^[16,17,51]

Symptomatic treatment will be similar to that of TMNGs.

Treatment of toxic adenoma

RAI and surgery are the therapeutic options for toxic adenoma. Pretreatment with antithyroid drugs and beta-blockers is needed in patients, especially in those with a high risk of complications.

RAI is preferred in older patients, prior surgery or scarring in the anterior neck, small goiter size, lack of access to surgery, and a RAIU that is sufficient to allow therapy. RAI needs to be given in a single sufficient dose. Follow-up for thyroid function test (FT4, total T3, and TSH) is evaluated after the RAI is within 1–2 months of treatment. Thereafter, biochemical monitoring is at every 4–6 week intervals for 6 months. If the patient becomes hypothyroid, monitoring is continued till the patient stabilizes on thyroid hormone supplementation. If hyperthyroidism persists after 6 months, retreatment with RAI is suggested.

Surgery by a high-volume surgeon is preferred in patients who have compressive symptoms, need to avoid radiation, and need immediate hyperthyroidism resolution. Following evaluation via ultrasound, an ipsilateral thyroid lobectomy or isthmectomy is performed in cases of isolated TAs. Post-surgical monitoring following lobectomy includes TSH and FT4 after 4–6 weeks. Persistent rise in TSH levels requires thyroid hormone supplementation.

Evidence for surgery and radioactive iodine in hyperthyroid patients, including multinodular goiter and toxic adenoma

A clinical study compared various preoperative preparation regimens for hyperthyroid patients undergoing thyroidectomy, excluding iodine preparations. Among 168 patients studied, procedure time, hospital stay duration, and overall complication rates were higher compared to euthyroid

patients, though operative blood loss did not significantly differ. The study suggests that iodine preparations may not be necessary for preoperative preparation, with lithium carbonate showing efficacy for refractory hyperthyroidism, and no significant difference in post-thyroidectomy complication rates between patients receiving thionamides alone or in combination with β -blockers.^[87]

In addition, a retrospective review of 325 hyperthyroidism patients managed surgically from 1990 to 2005 revealed varied etiologies, including GD (185), TMNG (105), and autonomously functioning thyroid nodules (35). Surgical indications included large goiter, relapse after ATD therapy, and the presence of nodules. Total thyroidectomy post-1995 provided immediate and permanent cure with negligible mortality and acceptable morbidity, suggesting surgery as a viable option for hyperthyroidism management, especially in experienced hands.^[88]

Findings from the evaluation of radioiodine therapy in 130 TMNG patients showed successful reversal of hyperthyroidism in 87% (low doses of RAI) and 82% (high doses of RAI) of patients. Hypothyroidism rates were 5% in the low-dose and 12.5% in the high-dose group, respectively, with no significant difference in total dose per gram of thyroid tissue. However, Group II, receiving calculated high doses, required fewer administrations and achieved hypothyroidism faster, suggesting lower post-therapy hypothyroidism incidence with low doses.^[89]

Results from a 20-year retrospective study on 3891 hyperthyroid patients revealed high remission rates with low-dose I-131 therapy (LDT), particularly within 12 weeks and predominantly among treatment-naïve patients with GD, TMNG, or autonomous toxic nodule. Factors such as lower FT4 levels, smaller goiter size, and shorter duration from hyperthyroidism onset to LDT correlated with higher remission rates, suggesting LDT's efficacy as a primary management option for hyperthyroidism.^[90]

Key summary points^[16,44,51]

Thyroid scans are useful for assessing thyroid nodularity, with different patterns observed in TA, and TMNG

In patients with TMNG and TA Beta-adrenergic blockade is recommended in all symptomatic thyrotoxicosis patients, particularly those with resting heart rates over 90 bpm or coexisting cardiovascular disease. Caution is advised in patients with bronchospastic asthma, where beta-blockers are generally contraindicated; in patients where RAI is the modality of treatment, beta-blockers are indicated even in asymptomatic patients and in patients at high risk of complications

MNG and TA patients with overt hyperthyroidism should be rendered euthyroid with carbimazole or methimazole before definitive treatment. The modality of treatment recommended is RAI, surgery, or long-term ATD

TMNG: Toxic multinodular goiters, TA: Toxic adenomas, RAI: Radioactive iodine, MNG: Multinodular goiter, ATDs: Antithyroid drugs

Thyroiditis

Thyroiditis may exhibit temporary thyrotoxicosis as a component of its classic triphasic course: Thyrotoxicosis, hypothyroidism, and eventual recovery. Types of thyroiditis include SAT, painless (silent) thyroiditis, acute (suppurative) thyroiditis, palpation (traumatic) thyroiditis, postpartum thyroiditis, and drug-induced thyroiditis. Thyroid dysfunction resulting from thyroiditis tends to be less severe compared to endogenous thyrotoxicosis.

Subacute thyroiditis

SAT (de Quervain thyroiditis) presents with thyroid pain, typically radiating to the ears, jaw, or throat. Diagnosis involves clinical history (malaise, low-grade fever, fatigue, and history of viral infection), physical examination, laboratory tests, and RAIU. The thyroid may be slightly enlarged, firm, and tender. About 50% of cases have an initial thyrotoxic phase due to thyroid hormone release from damaged follicular cells lasting for 3–6 weeks, followed by a hypothyroid phase in about 30% of patients that can persist for up to 6 months and a return to a euthyroid state within 12 months. Five to fifteen percent may develop persistent hypothyroidism, and recurrence rates of 1%–4% have been reported.^[16]

Thyroid pain/tenderness, elevated erythrocyte sedimentation rate (ESR), hyperthyroidism, hypoechoic ultrasound pattern, low uptake on thyroid scan, and specific findings on fine-needle aspiration can help in diagnosing SAT. Women are more predisposed to developing SAT and subsequent hypothyroidism.^[91] Additional findings include the presence of C-reactive protein levels, as well as mild anemia and increased WBC count. About 25% of patients may have reduced levels of antithyroid antibodies. RAIU and thyroid scintigraphy results are low, with thyroid ultrasound showing diffuse heterogeneity, focal hypoechoic areas, and decreased or normal color flow Doppler.

Therapy for initial mild symptomatic SAT with beta-adrenergic-blocking drugs and nonsteroidal anti-inflammatory agents (NSAIDs) should be considered.^[16] Average time for pain resolution with NSAIDs is 5 weeks (with a range of 1–20 weeks). If patients do not respond to initial treatment with a full dose of NSAID or present with moderate to severe pain and/or thyrotoxic symptoms, corticosteroids should be considered: prednisone at a dosage of 40 mg daily for 1–2 weeks, followed by a gradual taper over 2–4 weeks or longer based on individual clinical response. ATDs are not recommended for the treatment of SAT.^[16]

Painless thyroiditis

Painless or silent thyroiditis lacks the prodrome, neck pain, or elevated ESR, WBC count, or C-reactive protein. Commonly observed during the postpartum period, painless

thyroiditis can also occur in nonpregnant women and men, as well as in certain drug-induced thyroid dysfunction cases such as those associated with lithium or cytokine therapy. A small, nontender goiter is often present. 5%–20% of patients experience the thyrotoxic phase, lasting around 3–4 months, while the hypothyroid phase is more prevalent or more frequently identified, lasting up to 6 months. Most patients regain normal thyroid function within 12 months, but persistent hypothyroidism affects 10%–20% of individuals. Recurrence rates are approximately 5%–10%.^[16]

Painless thyroiditis likely represents an autoimmune disorder, as evidenced by the presence of positive antithyroid peroxidase antibodies in 50% of patients, along with lymphocytic infiltration histopathologically.^[16] Symptomatic individuals should receive treatment with beta-adrenergic-blocking drugs to alleviate symptoms. ATDs are not effective in this context, as there is already minimal new hormone synthesis in these patients. In rare severe cases, corticosteroids may be considered as a therapeutic option.^[16]

Acute thyroiditis

Treatment for acute thyroiditis involves antibiotics and, in some cases, surgery with beta-blockers for symptomatic management. Patients identified with acute thyroiditis, also recognized as suppurative thyroiditis or thyroid abscess, commonly display normal thyroid function (euthyroid). ATDs are not warranted in the treatment of this condition.^[16]

Amiodarone-induced thyrotoxicosis

Amiodarone-induced thyrotoxicosis (AIT) seen in iodine-deficient regions and in the male gender. AIT presents with typical symptoms of hyperthyroidism, except the cardiac symptoms may differ due to the underlying condition. If a patient is stable on amiodarone, suddenly undergoes re-emergence of cardiac condition, such as worsening of atrial fibrillation and palpitation, AIT must be suspected. In some cases, cardiac symptoms are the only clinical evidence for AIT. Thyroid function testing is recommended for such a patient.^[92,93]

There are two types of AIT: AIT 1 and AIT 2.

Amiodarone-induced thyrotoxicosis 1 (AIT 1) often occurs when there is an underlying thyroid disease such as MNG and GD. AIT 1 is common in iodine-deficient regions. Since Amiodarone contains iodine, which may cause iodine excess and lead to increased thyroid hormone biosynthesis, AIT 1 may occur. AIT 1 usually appears after around 3 months of starting Amiodarone. In the thyroid scintigraphy scans, I-131 uptake is high. In thyroid USG, a diffuse or nodular goiter pattern may be seen. Vascularity on Echo-color Doppler ultrasound is often increased. The T4/T3 ratio is <4. Antibodies such as TgAb, TPOAb, and TSI may

be present in AIT 1. Interleukin-6 levels are often normal. High dose ATD (MMI – 30–40 mg/day; CBZ 20–60 mg/day^[94,95] or PTU 400–600 mg/day) is given to block thyroid hormone synthesis. The dose is tapered to a low maintenance dose. Amiodarone should be stopped if feasible. In this case, ATDs are continued for the next 6–18 months and then discontinued based on the urine iodide levels. If amiodarone is continued, the patient must remain on the ATD. A modest response to ATD is expected since the iodine uptake levels are high. KClO₄ (potassium perchlorate) may be used to supplement the ATDs due to its iodine uptake blocking action. KClO₄ is associated with agranulocytosis or aplastic anemia, hence must be given <1 g/day and not more than 30 days. Lithium, along with an ATD, may also be given in cases of severe thyrotoxicosis for expedited recovery. Risk factors for severe thyrotoxicosis include more than 23 months on amiodarone and T4 > 50% above the upper limit of normal. RAI treatment can be considered if the radioiodine uptake is high. The possibility of overlap with AIT2 must be considered if there is worsening of the thyrotoxicosis after initial control of the disease.^[92,93]

AIT 2 is a result of the release of the preformed thyroid hormone due destruction of the thyroid tissue due to the toxic effect of amiodarone. AIT 2 may appear around 30 months after starting amiodarone. AIT 2 continues until the thyroid hormones depleted, which occurs in 1–3 months. The USG shows a normal or small gland, and the T4/T3 ratio is usually >4. Antibodies are usually absent in AIT 2.^[92] Type 2 AIT is treated with glucocorticoids for anti-inflammatory and membrane-stabilizing effects. Prednisolone can be given in the initial dose of 0.5–0.7 mg/kg body weight/day. Treatment is tapered and continued for 3 months. If worsening of the thyrotoxicosis during tapering of the treatment, then the dose of Prednisolone should be increased. Antithyroid drugs are not useful since the thyrotoxicosis is due to preformed thyroid hormones. After thyrotoxicosis resolution, hypothyroidism can develop, which requires thyroid hormone replacement therapy. Lithium may also benefit patients with AIT 2. Patients who do not respond to medical management should consider total thyroidectomy under careful cardiovascular monitoring.^[92,93]

Key summary points^[12,16,29,39,44,45,47,48,92-95]

Thyroiditis can be subacute, painless, acute, postpartum, or drug-induced. Diagnosis can be done by clinical history, physical examination, biochemical evaluation, and radioactive iodine uptake. Subacute and acute thyroiditis can be managed with the help of beta-blockers, NSAIDs, and, in some cases, corticosteroids. Symptomatic postpartum thyroiditis should be managed with a short course of Beta-blockers

Amiodarone-induced thyrotoxicosis can be diagnosed using by RAIU, T4/T3 ratio, and echo color Doppler. High dose ATD (carbimazole 20–60 mg/day) for 6 to 18 months is indicated in AIT type 1. Corticosteroids are indicated in AIT type 2

ATD: Antithyroid drug, NSAID: Nonsteroidal anti-inflammatory agents, AIT: Amiodarone-induced thyrotoxicosis

Thyroid Storm^[1,2,96]

Thyroid storm or thyrotoxic crisis is a life-threatening condition with high morbidity and mortality, which requires a prompt diagnosis and treatment. A decompensation across multiple organ systems occurs, which can manifest as altered consciousness, cardiac complications such as heart failure, diarrhea, jaundice, and high fever. Diagnostic criteria in patients who have been diagnosed as severe Graves' hyperthyroidism include tachycardia, arrhythmia, congestive heart failure, hyperpyrexia, agitation, delirium, psychosis, stupor, coma, diarrhea, vomiting, nausea, and hepatic failure. Such patients may also have an identified precipitant.

There can be several precipitating factors, which include

- Stopping antithyroid drugs abruptly
- Thyroid or nonthyroid surgery
- Trauma
- Acute disease conditions such as diabetic ketoacidosis, acute myocardial infection, cardiac failure, cardiovascular accidents, stroke, traumatic brain injury, and infections such as COVID-19
- Use of iodinated contrast medium
- Hyperemesis gravidarum or after parturition
- Burns
- Radioiodine therapy
- Drug side effects, such as amiodarone.

Burch-Wartofsky Point Scale

The Burch-Wartofsky Point Scale system measures the severity of the thyroid storm. A total score of ≥45 indicates thyroid storm, 25–44 as impending thyroid storm, and <25 scores indicates that thyroid storm is unlikely.

In 1993, the following scoring system for the diagnosis of thyroid storm was introduced:

- Temperature: 5 points for every 1°F above 99°F (maximum 30 points)
- Central nervous system dysfunction: 10 points for mild (agitation), 20 for moderate (delirium, psychosis, or extreme lethargy), and 30 for severe (seizure or coma)
- Tachycardia: 5 (99–109), 10 (110–119), 15 (120–129), 20 (130–139), and 25 (>140)
- Presence of atrial fibrillation: 10
- Heart failure: 5 for mild (pedal edema), 10 for moderate (bi-basilar rales), 15 for severe (pulmonary edema)
- Gastrointestinal (GI) dysfunction: 10 for moderate (diarrhea, nausea/vomiting, or abdominal pain) and 20 for severe (unexplained jaundice)
- Presence of precipitating factor: 10 points.

An early and aggressive treatment is required to reduce mortality. A multimodal treatment approach is required

for thyroid storm. General management includes oxygen and cardiac monitoring. For pyrexia, external cooling or acetaminophen 325–650 per oral (PO) or per rectal (PR) can be given. IV isotonic saline (or dextrose-containing isotonic saline can be used if low blood glucose is present).

CBZ 40–60 mg PO as a loading dose can be given, which can be continued till the patient becomes euthyroid or mildly hyperthyroid and then maintain the dose of 10–20 mg continues depending on the patient's thyroid report. MMI 40 mg orally as an initial loading dose and maintenance dose 25 mg every 4 h. Total daily dose: 120 mg/day. If given PR, 40 mg should be crushed in an aqueous solution. PTU, a loading dose of 600–1000 mg given PO followed by 200–250 mg every 4 h. Total daily dose: 1200–1500 mg/day.

IV MMI 40 mg 8 hourly or PTU 400 mg 8 hourly to reduce thyroid hormone synthesis may be required.

To reduce the thyroid hormone release, iodine is required. In order to block the peripheral conversion of T4 to T3, glucocorticoids, PTU, propranolol, and iodinated radio contrast are required. IV glucocorticoids such as i.v. Methylprednisolone 50 mg or hydrocortisone 100 mg IV every 8 h or dexamethasone 2 mg every 6 h can be started. Beta-blockers to control the increased sympathetic tone, such as propranolol 40–80 mg every 4–6 h or short-acting beta-blocker esmolol at a loading dose of 250 µg/kg to 500 µg/kg followed by 50 µg/kg to –100 µg/kg/min in an intensive care unit (ICU) setting can be given. Monitoring in the ICU is recommended. To reduce enterohepatic cycling of thyroid hormone, bile acid sequestrant, cholestyramine in doses of 4 mg four times daily is used.

PTU decreases T3 levels by 45% in the first 24 h of treatment but may cause hepatotoxicity. Methimazole causes only 10%–15% decrease in T3 levels in the first 24 h but has less hepatotoxicity, and hence, PTU should be switched to MMI after the initial stabilization.

Cause of death from thyroid storm is due to multiorgan failure, heart and respiratory failure, arrhythmia, GI perforation, sepsis, disseminated intravascular coagulation, and hypoxic brain syndrome.

Key summary points^[1,2,96]

The Burch-Wartofsky Point Scale system measures the severity of the thyroid storm. General management includes oxygen, cardiac monitoring, pyrexia management and Intravenous fluids. High dose antithyroid drugs, iodine, corticosteroids and beta-blockers are given to manage the thyrotoxicosis. ICU monitoring is recommended

ICU: Intensive care unit

Clinical Considerations For Women Of Childbearing Potential Group^[16]

- Women in the childbearing potential group and who develop hyperthyroidism should receive proper counselling and need to be informed regarding the impact of the disease and its management on pregnancy, with special consideration for family planning. It is recommended that a pregnancy test is done within the 1st days of a missed or an unusually light menstrual period, and contact of physician within 24 h if pregnancy is positive
- The condition of hyperthyroidism itself as well as the treatment for hyperthyroidism, leads to untoward consequences in pregnancy and fetal outcome; therefore, women should reach the euthyroid state before considering pregnancy. Two TFT tests within an interval of at least 1 month and without therapy change are used to demonstrate euthyroidism
- Definitive therapy of surgery and RAI should be considered in GD patients who require a high dose of ATD to become euthyroid. Thyroidectomy results in the decrease or disappearance of circulating TRAb. In case of RAI, there is an increase of transient TRAb, and pregnancy must be considered in >6 months following RAI treatment, provided normalization of thyroid hormone levels. TRAb levels must be measured using a sensitive assay during the first trimester and if elevated levels are found, there should be retesting at 18–22 weeks of gestation. If TRAb levels are raised at 18–22 weeks of gestation, TRAb should be retested at late pregnancy at week 30–34 in order to investigate the need for neonatal monitoring.

Hyperthyroidism in pregnancy and lactation

According to Kumar et al.^[97] 2023 study in Punjab, the prevalence of thyroid disorders in 300 pregnant women was identified via TSH screening, and if TSH was found to be abnormal, further T3 and T4 testing was done. Hyperthyroidism was found in 7 (2.3%) of pregnancies. The main complication associated with hyperthyroidism was abortion found in 5 (71.4%) of hyperthyroid pregnancies.^[97]

Overt hyperthyroidism in pregnancy is also diagnosed with the help of thyroid function test with TSH <0.1 mIU/L and thyroid hormones (FT4 and total T3) that are above the reference ranges for pregnancy. In cases of suspected pregnancy with hyperthyroidism, it is necessary to distinguish between GD and cases of GTT such as hyperemesis gravidarum.^[98,99]

In preparation for pregnancy, the maternal thyroid gland undergoes several physiological alterations. GTT is a condition where hCG produced by the placenta induces

Table 1: Prevalence of overt hyperthyroidism in India^[4-11]

Indian study	Patient population							
	Screening studies in communities					Studies in Hospitals		
	Unnikrishnan and Menon <i>et al.</i> ^[4]	Marwaha <i>et al.</i> ^[5]	Ganie <i>et al.</i> ^[6]	Abraham <i>et al.</i> ^[7]	Velayutham <i>et al.</i> ^[8]	Bose <i>et al.</i> ^[9]	Nirmalanandan <i>et al.</i> ^[10]	Sahu and John ^[11]
State	Kerala	Delhi	Jammu and Kashmir	Puducherry	Tamil Nadu	Madhya Pradesh	Kerala	Odisha
Prevalence (%)	1.3	1.1	0.9	1.2	1.5	1.79	2.5	5.3
Patient population	Population-based study on 971 adult subjects	4409 adult members of resident welfare associations of 5 residential colonies	768 individuals from 5 districts of Jammu and Kashmir	505 women who attended a Health Clinic	1292 female college students in seven colleges in Madurai District	28,677 patients who were turned out to hospital for thyroid hormone profile tests	2401 admitted in the general ward with thyroid disorders	9649 requisition forms for TFTs, from patients in a tertiary care center

TFT: Thyroid function test

Table 2: Signs and symptoms of hyperthyroidism^[12,18]

System	Symptoms	Signs
General	Weight loss Fatigue Weakness esp. in elderly Heat intolerance Increased appetite	Increased sweating Hoarseness of voice
Cardiovascular	Palpitations Ankle edema	Tachycardia with/without irregular rhythm Atrial fibrillation Wide pulse pressure Systolic hypertension Heart failure
Neuropsychiatry	Restlessness, Anxiety Sleep disturbances Depression Poor concentration Tremors Muscle weakness Periodic Paralysis	Brisk tendon reflexes Finger or tongue tremor Muscle wasting
Reproductive	Oligomenorrhea Irregular menstrual cycles Impaired libido in men	Subfertility in women
Gastrointestinal	Loose stools, diarrhea, nausea	Increase in frequency of bowel movements
Musculoskeletal	Fragility fractures	Unexplained osteoporosis
Endocrinology	Goiter	Gynecomastia Pretibial myxedema
Ophthalmology	Bulging eyes Stare	Upper lid retraction
Dermatology		Plummer's nail Warm moist skin

the TSH receptor to produce thyroid hormones T3 and T4. Compared to a nonpregnant woman, the serum concentration of TSH is also reduced. GTT presents with symptoms similar to GD, such as anxiety, tremors, palpitations, and heat intolerance. In conditions with exaggerated hCG production, such as in trophoblastic disease, hyperemesis gravidarum, or multiple pregnancies, the GTT symptoms can be severe.^[100-102]

Often, the diagnosis of hyperthyroidism can remain elusive due to the fluctuating nature of the thyroid hormones. It is necessary to distinguish GTT from GD. GTT is a transient condition and mild in nature, and therefore does not require treatment with ATD. GD is associated with maternal and fetal adverse outcomes and hence needs careful management with appropriate ATDs and monitoring. TRABs are of special significance in such cases since positive TRAb can help confirm GD and can differentiate

Table 3: Comparison of biological assays and thyroid stimulating hormone binding inhibition

	Biological assays	TBII
Pros	Differentiates between blocking and stimulating TRAb	Is easy to perform and standardize Results achieved in shorter duration 2 nd and 3 rd generation TBII assays are very sensitive Is commercially available
Cons	Time consuming May not be accessible as it a research-based testing Is technically difficult	Does not differentiate between blocking and stimulating TRAb Dose not correlate with severity of illness

Commercial assays of thyroid antibody testing have predetermined cut-offs for the diagnosis of Graves' disease. TBII: Thyroid stimulating hormone binding inhibition immunoglobulin, TRAb: Thyrotropin receptor antibodies

Table 4: Beta-adrenergic receptor blockade in the treatment of thyrotoxicosis^[16]

Drug ^a	Dosage	Frequency	Considerations
Propanolol	10–40 mg	3–4 times per day	Nonselective β -adrenergic receptor blockade Longest experience May block T4–T3 conversion at high doses Preferred agent for nursing and pregnant mothers
Atenolol	25–100 mg	1–2 times per day	Relative β_1 selectivity Increased compliance Avoid during pregnancy
Metoprolol ^b	25–50 mg	2–3 times per day	Relative β_1 selectivity
Nadolol	40–160 mg	1 time per day	Nonselective β -adrenergic receptor blockade Once daily Least experience to date May block T4–T3 conversion at high doses
Esmolol	IV pump 50–100 μ g/kg/min		In intensive care unit setting of severe thyrotoxicosis or storm

^aEach of these drugs are approved for treatment of cardiovascular diseases, but to date none has been approved for the treatment of thyrotoxicosis, ^bAvailable in once daily preparation

Table 5: Candidates for antithyroid drugs

Clinical situations
Patients with high likelihood of remission (mild disease, small goiters, and negative or low-titer TRAb); pregnancy
The elderly or comorbidities increasing surgical risk or with limited life expectancy
Individuals in nursing homes or other care facilities
Previously operated or irradiated necks
Lack of access to a high-volume thyroid surgeon
Moderate to severe active GO
Patients who need more rapid biochemical disease control

TRAb: Thyrotropin receptor antibodies, GO: Graves' ophthalmopathy/orbitopathy

Table 6: Initial dose of antithyroid drugs in the treatment of hyperthyroidism^[53]

Baseline Free T4 elevation	CBZ (mg)	MMI (mg)	PTU (mg)
1–1.5 $\times$ ULN	10–15	5–10	100–200
1.5–2 $\times$ ULN	20–30	10–20	200–400
2–3 $\times$ ULN	50–70	30–40	600–800

ULN: Upper limit of normal, CBZ: Carbimazole, MMI: Methimazole, PTU: Propylthiouracil

from the GTT. Presence of Graves' orbitopathy, goiter, and previous GH are also indicative of the diagnosis of GD.^[34,100,101] It is important to elicit a history of GD in pregnant women who have undergone Radioiodine ablation treatment or surgery, since the circulating TRAb may persist and lead to fetal thyrotoxicosis. In euthyroid pregnant women with a history of GD who achieved remission with ATDs (with intact thyroid) and are currently not on treatment, TRAb testing is not indicated.^[16]

Diagnosed GTT as well as subclinical hyperthyroidism can be managed with observation without treatment, with continuous monitoring of thyroid function test every 4–6 weeks. Untreated overt hyperthyroidism can lead to adverse maternal outcomes and increased fetal loss; therefore, treatment with ATDs is necessary in spite of their ability to cause teratogenicity.^[100]

PTU is preferred in the first trimester due to the association of CBZ and MMI with choanal atresia, aplasia cutis, abdominal wall defects, esophageal atresia, eye abnormalities, urinary tract abnormalities, and defects in circulation. After the completion of organogenesis in the first trimester, the patient can be transitioned to CBZ or MMI since PTU is associated with hepatotoxicity.^[100] In case of intolerance or allergy to PTU, the patient may be given CBZ or MMI. The lowest possible antithyroid dose for maintaining effectiveness must be used.^[99,103]

Maternal TRAbs are immunoglobulin G protein type, which can cross the placenta and stimulate the fetal thyroid gland, causing fetal hyperthyroidism. ATDs can cross the placenta and control the fetal hyperthyroidism. A caution must be undertaken to prevent fetal hypothyroidism while the patient is on ATD. Therefore, the goal of treatment is to use the lowest ATD dose in order to target the TSH to a value that is slightly lower than the reference range and a T4 that is on

the higher end of the normal reference range. A maternal state of mild hyperthyroidism, with careful monitoring to prevent fetal hypothyroidism, should be achieved. If it is observed that the TSH is normalized, beta-blockers such as propranolol may provide symptomatic relief. Propranolol is preferred over atenolol due to decreased birth weight being associated with atenolol. Beta-blockers must always be given for a short term to control the symptoms of hyperthyroidism. Long-term beta-blockers may increase the risk of intrauterine

fetal growth retardation. Iodides are contraindicated due to the risk of fetal goiter.^[16,103]

In cases of GD treated with thyroidectomy or RAI, maternal euthyroidism combined with a positive TRAb test can be seen in pregnancy. In such cases, TRAb evaluation must be done in the first trimester along with the thyroid function test. If the TRAb levels are elevated at first trimester evaluation, a reassessment must be done at 18–22 weeks of gestation. This may lead to fetal thyrotoxicosis and can be detected clinically as fetal tachycardia (Fetal heart rate >160). Re-evaluation should occur in 2 weeks with the help of fetal ultrasound (improvement in fetal heart rate and resolution of goiter) In such cases, block-replace regimen of ATDs can treat fetal thyrotoxicosis since ATDs can cross the placenta, while levothyroxine, which does not cross the placenta, can maintain maternal euthyroidism. In patients with raised TRAb levels at 18–22 weeks, the TRAb levels need to be reassessed at 30–34 weeks to guide clinical decisions related to neonates.^[16]

In pregnant women with overt hyperthyroidism and where the diagnosis is determined to be MNG or toxic adenoma, antithyroid drugs may be given. Adequate care must be undertaken to prevent fetal hypothyroidism in such cases, since unlike GD, TRAb are not present to stimulate the thyroid gland.^[16]

In women developing thyrotoxicosis in the postpartum period, there is a need to distinguish postpartum destructive thyroiditis and postpartum GD. Postpartum thyroiditis follows the triphasic course: Thyrotoxicosis emerging at 1–6 months postpartum, followed by hypothyroidism and euthyroidism at 9–12 months. Symptomatic postpartum thyroiditis should be managed with a short course of beta-blockers. Postpartum GD emerges at 3–12 months after delivery and may be characterized by pronounced goiter, thyroid bruit, and Graves' ophthalmopathy. While TRAb may be present in patients with both postpartum thyroiditis and postpartum Graves' disease, higher TRAb levels may be present in women with postpartum GD. T3 to T4 ratio is

Table 7: Duration recommendation for Graves' Disease

Guideline	Duration of drug therapy
ATA guidelines (2016) ^[16]	If CBZ or MMI is chosen as the primary therapy for GD, the medication should be continued for approximately 12–18 months Discontinue CBZ or MMI if TSH and TRAb levels are normal at that time
ETA guidelines (2018) ^[2]	The optimal duration of ATD therapy for the titration regimen is 12–18 months
NICE guidelines (2019) ^[52]	When offering antithyroid drugs as first-line definitive treatment to adults with GD, CBZ should be offered for 12–18 months Use either a block and replace or a titration regimen during this period Review the need for further treatment after 12 to 18 months

ATA: American Thyroid Association, CBZ: Carbimazole, MMI: Methimazole, TRAb: Thyrotropin receptor antibodies, GD: Graves' Disease, TSH: Thyroid stimulating hormone, ETA: European Thyroid Association, NICE: National Institute for Health and Care Excellence

Table 8: Evidence for low dose carbimazole for maintenance dose

Study	Findings / Outcome
Trabucco et al. ^[68]	66% patients with GD, a very low daily dose of carbimazole which was <5 mg was effective and had resulted a remission rate of 54%
Baek et al. ^[69]	Carbimazole was given in a mean dose of 2.3 mg for 3 years which resulted in relapse rate of 15.8%
Kon et al. ^[70]	Author describes 5 cases of GD, who on conventional doses 5–15 mg of carbimazole switched to hypothyroidism. In one patient FT4 showed a fluctuating yo-yo pattern. This also led to low normal or low FT4, low/mid normal serum TSH at normal FT3 levels. To maintain euthyroidism and to prevent rebound thyrotoxicosis patients were given Carbimazole 2.5 mg daily or 2.5 mg biweekly

TSH: Thyroid stimulating hormone, FT4: Free thyroxine, FT3: Free tri-iodothyronine, GD: Graves' disease

Table 9: Adverse events associated with antithyroid drugs

Within the first few weeks of treatment initiation	Approximately 5 weeks	Within the initial 90 days of starting treatment
Minor side effects, such as pruritic rash and arthralgias, occur in roughly 5% Rash may resolve with continuous medication or with antihistamines, but it could be severe enough to need drug withdrawal Carbimazole/methimazole may be switched to propylthiouracil, although 30%–50% had a similar reaction	Hepatotoxicity (Usually cholestatic) Mean time to onset: 36 days Incidence <0.1%	Agranulocytosis Incidence is 0.3%–0.6% with a mortality rate of 21.5% Dose related adverse event Can also occur owing to re-exposure to the medication after several years Typical symptoms include high fever and severe pharyngitis Resolution: Immediate drug discontinuation, hospitalization, and provision of broad-spectrum antibiotics and hematopoietic growth factor treatment

high in Graves' disease relative to destructive thyroiditis. Thyroid USG may be adopted to distinguish Graves' disease and thyroiditis. Radioactive scintigraphy scans to diagnose the cause of postpartum thyrotoxicosis should be avoided to prevent disruption in breastfeeding, as well as to prevent exposure of the breast to radiation.^[16]

According to the 2016 American Thyroid Association guidelines, the following practice points may be undertaken in a hyperthyroid pregnancy.^[16]

- CBZ^[104] and MMI are associated with increased risk of congenital association
 - Patient can switch to PTU before conceiving or as soon as pregnancy is diagnosed, especially in patients with recurrent or worsening hyperthyroidism
 - ATD can be withdrawn in some appropriate patient candidates in whom relapse risk is low (severity of disease, ATD treatment duration, TRAb, and TFT test results) as soon as pregnancy is detected; however, Thyroid function must be monitored weekly in the first trimester and then monthly
 - After the first trimester, the patient can be switched to CBZ or MMI in the second trimester or can be continued for the rest of the pregnancy
 - The lowest possible dose of ATD should be used during pregnancy to keep maternal thyroid hormone levels at or slightly above the reference range of total T4 and T3 levels in pregnancy and TSH below the reference range for pregnancy. FT4 levels should be above the upper limit of the trimester reference range
 - Monitoring should be undertaken at least a monthly interval to allow for the titration of the ATD dose
 - Patients can consider definitive treatment before becoming pregnant
- Thyroidectomy is relatively contraindicated in pregnancy and is utilized if ATDs are contraindicated; if this approach is used, surgery should be conducted in the second trimester. Surgery may also be indicated if ATDs fail to control hyperthyroidism at high doses (PTU 300 mg/day; MMI or CBZ 40 mg/day)^[98]
- If the cause of hyperthyroidism is not ascertained, TRAb testing must be done.

Management of hyperthyroidism in lactation

Use of antithyroid drug in lactation^[105,106]

- CBZ has been studied in doses of 30 mg daily or 50 mg weekly in few mothers of breastfed infants and has not shown any adverse effects
- MMI in doses up to 20 mg daily in a lactating mother has not been seen to affect the thyroid function or intellectual development of breastfed infants
- To minimize the infant dose, MMI can be taken right

after nursing and waiting for 3–4 h before nursing

- Beta-blockers such as propranolol and metoprolol are secreted in the breast milk in very low amounts and can be used for symptomatic control of thyrotoxicosis
- Routine pediatric health monitoring must be undertaken for infants for growth and development
- Routine thyroid function test is not recommended for children
- Suspicion of drug-induced dyscrasia should be confirmed with the monitoring of the infant's complete blood count and differential blood count.

Key summary points

Proper counselling is required in women with hyperthyroidism since the condition of hyperthyroidism itself, as well as the treatment for hyperthyroidism, leads to untoward consequences in pregnancy and fetal outcome

Women should reach the euthyroid state before considering pregnancy. Two TFT tests within an interval of at least 1 month and without therapy change are used to demonstrate euthyroidism

Definitive therapy of surgery and RAI should be considered in women with hyperthyroidism desirous of pregnancy who require high dose of ATD to become euthyroid. In case of RAI, there is an increase of transient TRAb, and pregnancy must be considered in >6 months following RAI treatment, provided normalization of thyroid hormone levels

In pregnancy, the cause of hyperthyroidism is not ascertained, TRAb testing must be done

Once pregnancy is confirmed, hyperthyroid patient can switch to PTU before conceiving or as soon as pregnancy is diagnosed. After the first trimester, the patient can be switched to carbimazole or methimazole in the second trimester or can be continued for the rest of the pregnancy

Thyroidectomy is relatively contraindicated in pregnancy and is utilized if ATDs are contraindicated; if this approach is used, surgery should be conducted in the second trimester

Antithyroid may be given in lactating mothers. To minimize the infant dose, antithyroid drug can be taken right after nursing and waiting for 3–4 h before nursing. Routine pediatric health monitoring must be undertaken for infants for growth and development. Suspicion of drug-induced dyscrasia should be confirmed with the monitoring of the infant's complete blood count and differential blood count

RAI: Radioactive iodine, ATDs: Antithyroid drugs, PTU: Propylthiouracil, TRAb: Thyrotropin receptor antibodies, TFT: Thyroid function test

Author contribution

Shashank Joshi: Conceptualization, Methodology, Resources, Supervision, Validation, Reviewing. Krishna Seshadri: conceptualization, Methodology, Resources, Supervision, Validation, Reviewing. Sujoy Ghosh: Conceptualization, Methodology, Resources, Supervision, Validation, Reviewing. Pramila Kalra3: Conceptualization, Methodology, Resources, Supervision, Validation, Reviewing. Arun S. Menon: Resources, Supervision, Validation, Reviewing. Himagirish K. Rao: Resources, Supervision, Validation, Reviewing. Mini G. Pillai: Resources, Supervision, Validation, Reviewing. Sarita Bajaj: Resources, Supervision, Validation, Reviewing. Rajesh Rajput: Resources, Supervision, Validation, Reviewing.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Idrose AM. Acute and emergency care for thyrotoxicosis and thyroid storm. *Acute Med Surg* 2015;2:147-57.
- Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of Graves' hyperthyroidism. *Eur Thyroid J* 2018;7:167-86.
- Doubleday AR, Sippel RS. Hyperthyroidism. *Gland Surg* 2020;9:124-35.
- Unnikrishnan AG, Menon UV. Thyroid disorders in India: An epidemiological perspective. *Indian J Endocrinol Metab* 2011;15:S78-81.
- Marwaha RK, Tandon N, Ganie MA, Kanwar R, Sastry A, Garg MK, *et al.* Status of thyroid function in Indian adults: Two decades after universal salt iodization. *J Assoc Physicians India* 2012;60:32-6.
- Ganie MA, Charoo BA, Sahar T, Bhat MH, Ali SA, Niyaz M, *et al.* Thyroid function, urinary iodine, and thyroid antibody status among the tribal population of Kashmir Valley: Data from endemic zone of a sub-Himalayan region. *Front Public Health* 2020;8:555840.
- Abraham R, Srinivasa Murugan V, Pukazhvanthen P, Sen SK. Thyroid disorders in women of Puducherry. *Indian J Clin Biochem* 2009;24:52-9.
- Velayutham K, Selvan SS, Unnikrishnan AG. Prevalence of thyroid dysfunction among young females in a South Indian population. *Indian J Endocrinol Metab* 2015;19:781-4.
- Bose A, Sharma N, Hemvani N, Chitnis DS. A hospital based prevalence study on thyroid disorders in Malwa region of Central India. *Int J Curr Microbiol App Sci* 2015;4:604-11.
- Nirmalanandan MK, Balachandran KJ. A prospective study to analyze the etiology, prevalence, clinical presentation, age and sex wise distribution of thyrotoxicosis among thyroid disorders in a tertiary care hospital. *International Surgery Journal*. 2020;7:2965-9.
- Sahu S, John J. Investigating investigation (Ab)use: Thyroid function test audit in a tertiary care teaching institute in Eastern India. *Indian J Clin Biochem* 2022;37:499-503.
- Wiersinga WM, Poppe KG, Efraimidis G. Hyperthyroidism: Aetiology, pathogenesis, diagnosis, management, complications, and prognosis. *Lancet Diabetes Endocrinol* 2023;11:282-98.
- Agrawal PG, Khopkar US, Mahajan SA, Mishra SN. Triads in dermatology. *Indian J Dermatol* 2013;58:346-51.
- Medeiros-Neto G. Multinodular Goiter. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, *et al.*, editors. *Endotext*. South Dartmouth (MA): MDText.com, Inc.; 2000.
- Kaur G, Anand T, Bhatnagar N, Kumar A, Jha D, Grover S. Past, present, and future of iodine deficiency disorders in India: Need to look outside the blinkers. *J Family Med Prim Care* 2017;6:182-90.
- Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, *et al.* 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid* 2016;26:1343-421.
- Mulita F, Anjum F. Thyroid Adenoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562252/>. [Last updated on 2023 Apr 27].
- Nijith L, Ranjan R. Cardiovascular manifestations in hyperthyroidism: A cross-sectional study in a tertiary care hospital in South India. *Cureus* 2022;14:e25232.
- Philip R, Sivaraman Nair SA, Kuruvilla V, John SM, Amal D, Sankaran KC. Incidentally detected thyrotoxicosis-etiology and natural course: A study from Central Kerala. *CHRISMED J Health Res* 2016;3:203-6.
- Braverman, Lewis E. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. 10th ed. 2020; p. 496.
- Orgiazzi J, Millot L. Theoretical aspects of the treatment with antithyroid drugs. *Ann Endocrinol (Paris)* 1994;55:1-5.
- Goswami R, Seth A, Goswami AK, Kochupillai N. Prevalence of enuresis and other bladder symptoms in patients with active Graves' disease. *Br J Urol* 1997;80:563-6.
- Asif H, Nwachukwu I, Khan A, Rodriguez G, Bahtiyar G. Hyperthyroidism presenting with mania and psychosis: A case report. *Cureus* 2022;14:e22322.
- Mishra KK, Sawant N, Garg S. Management of psychiatric disorders in patients with endocrine disorders. *Indian J Psychiatry* 2022;64:S402-13.
- Goyal MK, Yadav KS, Solanki RK. A study of thyroid profile in patients suffering from the first episode of mania: A cross-sectional study. *Indian J Psychiatry* 2021;63:395-9.
- Wu W, Sun Z, Yu J, Meng Q, Wang M, Miao J, *et al.* A clinical retrospective analysis of factors associated with apathetic hyperthyroidism. *Pathobiology* 2010;77:46-51.
- Blick C, Nguyen M, Jialal I. Thyrotoxicosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482216/>. [Last updated on 2023 Jul 04].
- Marwaha RK, Tandon N, Ganie MA, Mehan N, Sastry A, Garg MK, *et al.* Reference range of thyroid function (FT3, FT4 and TSH) among Indian adults. *Clin Biochem* 2013;46:341-5.
- Narkar RR, Mishra I, Baliarsingha AK, Choudhury AK. Rapid differential diagnosis of thyrotoxicosis using T3/T4 Ratio, FT3/FT4 ratio and color Doppler of thyroid gland. *Indian J Endocrinol Metab* 2021;25:193-7.
- Nguyen CT, Mestman JH. Graves' hyperthyroidism in pregnancy. *Curr Opin Endocrinol Diabetes Obes* 2019;26:232-40.
- Jacob JJ. TSH receptor antibodies (TRAb) Assay: An underutilized test in India. *Indian J Endocrinol Metab* 2022;26:1-3.
- Kim HJ. Long-term management of graves disease: A narrative review. *J Yeungnam Med Sci* 2023;40:12-22.
- Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. *J Clin Endocrinol Metab* 2013;98:2247-55.
- Nguyen CT, Sasso EB, Barton L, Mestman JH. Graves' hyperthyroidism in pregnancy: A clinical review. *Clin Diabetes Endocrinol* 2018;4:4.
- Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves' orbitopathy. *J Endocrinol Invest* 2021;44:703-12.
- Lee SY, Pearce EN. Hyperthyroidism: A review. *JAMA* 2023;330:1472-83.
- John M, Jagesh R, Unnikrishnan H, Jalaja MM, Oommen T, Gopinath D. Utility of TSH receptor antibodies in the differential diagnosis of hyperthyroidism in clinical practice. *Indian J Endocrinol Metab* 2022;26:32-7.
- Malik SA, Choh NA, Misgar RA, Khan SH, Shah ZA, Rather TA, *et al.* Comparison between peak systolic velocity of the inferior thyroid artery and technetium-99m pertechnetate thyroid uptake in differentiating Graves' disease from thyroiditis. *Arch Endocrinol Metab* 2019;63:495-500.
- Giovanella L. Update on diagnosis and treatment of hyperthyroidism. *Q J Nucl Med Mol Imaging* 2021;65:89-90.
- Małkowski B, Serafin Z, Glonek R, Suwała S, Łopatto R, Junik R. The role of (18)F-FDG PET/CT in the management of the autoimmune thyroid diseases. *Front Endocrinol (Lausanne)* 2019;10:208.
- Bhamare SB, Maru A, More MY, Pagar S, Pawar D, Deore P. An overview on hyperthyroidism. *World J Pharm Res* 2020;9:433-42.
- Raguthu CC, Gajjela H, Kela I, Kakarala CL, Hassan M, Belavadi R, *et al.* Cardiovascular involvement in thyrotoxicosis resulting in heart failure: The risk factors and hemodynamic implications. *Cureus* 2022;14:e21213.
- Shahid MA, Ashraf MA, Sharma S. Physiology, thyroid hormone. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK500006/>. [Last updated on 2023 Jun 05].

44. Verapamil Controls Atrial Fibrillation Associated with Hyperthyroidism. *Inpharma Wkly* 1987;592:13.
45. Milner MR, Goldman ME. Diltiazem for the treatment of thyrotoxicosis. *Arch Intern Med* 1989;149:1217.
46. Rivas AM, Pena C, Kopel J, Dennis JA, Nugent K. Hypertension and hyperthyroidism: Association and pathogenesis. *Am J Med Sci* 2021;361:3-7.
47. Abraham P, Acharya S. Current and emerging treatment options for Graves' hyperthyroidism. *Ther Clin Risk Manag* 2010;6:29-40.
48. Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. *Am J Med* 1992;93:61-8.
49. Motashaw MD. Treatment of angina pectoris with antithyroid drug (Carbimazole). *J Assoc Physicians India* 1963;11:293-8.
50. Kalra S, Bajaj S, Mithal A. Endocrinology and the essential list. *Indian J Endocrinol Metab* 2012;16:S133-5.
51. National Institute for Health and Care Excellence. Thyroid Disease: Assessment and management. London: National Institute for Health and Care Excellence (NICE); 2019.
52. Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, *et al.* Graves' disease. *Nat Rev Dis Primers* 2020;6:52.
53. Burch HB, Cooper DS. Anniversary review: Antithyroid drug therapy: 70 years later. *Eur J Endocrinol* 2018;179:R261-74.
54. Medsafe. New Zealand data sheet: Carbimazole 5 mg tablet (Neo-Mercazoletab.pdf). New Zealand Medicines and Medical Devices Safety Authority. Retrieved from: <https://www.medsafe.govt.nz/profs/datasheet/n/Neo-Mercazoletab.pdf>. 2024.
55. Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: An evidence-based approach to therapeutic controversies. *J Clin Endocrinol Metab* 2003;88:3474-81.
56. MacFarlane IA, Davies D, Longson D, Shalet SM, Beardwell CG. Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease. *Clin Endocrinol (Oxf)* 1983;18:557-61.
57. Gupta SK, Mithal A, Godbole MM. Single daily dose of carbimazole in the treatment of hyperthyroidism. *Natl Med J India* 1992;5:214-6.
58. Gilbert J. Thyrotoxicosis – Investigation and management. *Clin Med (Lond)* 2017;17:274-7.
59. Yap PK. Single daily dose carbimazole in the treatment of Grave's disease. *Singapore Med J* 1979;20:447-50.
60. Paragliola RM, Di Donna V, Locantore P, Papi G, Pontecorvi A, Corsello SM. Factors predicting time to TSH normalization and persistence of TSH suppression after total thyroidectomy for Graves' disease. *Front Endocrinol (Lausanne)* 2019;10:95.
61. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R. Carbimazole and the autoimmune response in Graves' disease. *N Engl J Med* 1980;303:302-7.
62. Morales García F, Cayuela A, García Hernández N, Losada Viñau F, Mangas Cruz MÁ, Martínez Brocca MA, *et al.* Long-term maintenance of low-dose antithyroid drugs versus drug withdrawal in patients with Graves' hyperthyroidism. *Endocrinol Nutr* 2008;55:123-31.
63. Azizi F, Mehran L, Abdi H, Amouzegar A. Approach to the patient considering long-term antithyroid drug therapy for Graves' disease. *J Clin Endocrinol Metab* 2024;109:e1881-8.
64. Azizi F, Abdi H, Mehran L, Amouzegar A. Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: A systematic scoping review. *J Endocrinol Invest* 2022;45:1139-50.
65. Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: A systematic review and meta-analysis. *Thyroid* 2017;27:1223-31.
66. Campbell K, Doogue M. Evaluating and managing patients with thyrotoxicosis. *Aust Fam Physician* 2012;41:564-72.
67. Stockigt JR. Thyroid dysfunction and goitre: therapeutic dilemmas. *Australian Prescriber*. 1994;17.
68. Trabucco P, Engler H, Ryff-de Lèche A, Althaus B, Staub JJ. Carbimazole therapy in Basedow's disease: Therapy results in individual dosage adjustment. *Schweiz Med Wochenschr* 1989;119:1894-8.
69. Baek HS, Lee J, Jeong CH, Lee J, Ha J, Jo K, *et al.* The prediction model using thyroid-stimulating immunoglobulin bioassay for relapse of Graves' disease. *J Endocr Soc* 2022;6:bvac023.
70. Kon YC, Ping Lim BS, Lee Y, Aw SE, Yoke Wong YK. Agoutrous Graves' hyperthyroidism with markedly elevated thyroid stimulating immunoglobulin titre displaying rapid response to carbimazole with discordant thyroid function. *J ASEAN Fed Endocr Soc* 2020;35:224-32.
71. Azizi F, Abdi H, Amouzegar A. Control of Graves' hyperthyroidism with very long-term methimazole treatment: A clinical trial. *BMC Endocr Disord* 2021;21:16.
72. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, *et al.* The 2021 European group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. *Eur J Endocrinol* 2021;185:G43-67.
73. Stockigt J. Thyroid dysfunction and goiter: Therapeutic dilemmas. *Aust Prescr* 1994;17:70-2.
74. Burch HB, Cooper DS. Management of Graves disease: A review. *JAMA* 2015;314:2544-54.
75. Santos Palacios S, Pascual-Corrales E, Galofre JC. Management of subclinical hyperthyroidism. *Int J Endocrinol Metab* 2012;10:490-6.
76. Mohan A, Joseph S, Sidharthan N, Murali D. Carbimazole-induced agranulocytosis. *J Pharmacol Pharmacother* 2015;6:228-30.
77. Fernandes ASC. Update on Graves' ophthalmopathy (Master's thesis, Universidade de Lisboa (Portugal)) 2016.
78. Reddy SV, Jain A, Yadav SB, Sharma K, Bhatia E. Prevalence of Graves' ophthalmopathy in patients with Graves' disease presenting to a referral Centre in North India. *Indian J Med Res* 2014;139:99-104.
79. Roy A, Dutta D, Ghosh S, Mukhopadhyay P, Mukhopadhyay S, Chowdhury S. Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves' orbitopathy: A randomized controlled trial. *Indian J Endocrinol Metab* 2015;19:351-8.
80. Li H, Yang L, Song Y, Zhao X, Sun C, Zhang L, *et al.* Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: A systematic review and network meta-analysis. *Acta Ophthalmol* 2022;100:e1189-98.
81. Gupta R, Thomas R, Almkhatar F, Kiran A. Visual morbidity in thyroid eye disease in Asian Indian patients. *Indian J Ophthalmol* 2020;68:1622-7.
82. Hu Y, Chen J, Lin K, Yu X. Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves' ophthalmopathy: a systematic review and meta-analysis. *Front Endocrinol (Lausanne)*. 2023;14:1160936. doi: 10.3389/fendo.2023.1160936.
83. Jerusha TR, Harshitha VS, Rekha B, Swetha P, Balaprabha GR, Rao R. Multinodular Goiter. 2022;3:349-51.
84. Azizi F, Saadat N, Takyar MA, Abdi H, Mehran L, Amouzegar A. Efficacy and safety of long-term methimazole versus radioactive iodine in the treatment of toxic multinodular goiter. *Endocrinol Metab (Seoul)* 2022;37:861-9.
85. Mulita F, Anjum F. Thyroid adenoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
86. Mulita F, Anjum F. Thyroid adenoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562252/>. [Last updated on 2023 Apr 27].
87. Nair GC, Babu MJ, Menon R, Jacob P. Preoperative preparation of hyperthyroidism for thyroidectomy – Role of supersaturated iodine and lithium carbonate. *Indian J Endocrinol Metab* 2018;22:392-6.
88. Pradeep PV, Agarwal A, Baxi M, Agarwal G, Gupta SK, Mishra SK. Safety and efficacy of surgical management of hyperthyroidism: 15-year experience from a tertiary care center in a developing country. *World J Surg* 2007;31:306-12.
89. Khanna CM, Magdum M, Ravishankar L, Dham DN, Chugh P. Evaluation of long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy (I 131). *J Assoc Physicians India* 1996;44:102-5.
90. Shrinivas Yuvan S, Padma S, Sundaram PS. Factors predicting

- remission in hyperthyroid patients after low-dose I-131 therapy: 20 years retrospective study from a tertiary care hospital. *Ann Nucl Med* 2024;38:231-7.
91. Görges J, Ulrich J, Keck C, Müller-Wieland D, Diederich S, Janssen OE. Long-term outcome of subacute thyroiditis. *Exp Clin Endocrinol Diabetes* 2020;128:703-8.
92. Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: A review. *Can J Cardiol* 2009;25:421-4.
93. Macchia PE, Feingold KR. Amiodarone induced thyrotoxicosis. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, *et al.*, editors. *Endotext*. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279030/>. [Last updated on 2022 Jun 01].
94. Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. *Circulation* 2002;105:1275-7.
95. Arnold A. Primary Hyperparathyroidism: Molecular Genetic insights and Clinical Implications. Presented at Society for Endocrinology BES 2017, Harrogate, UK. *Endocrine Abstracts* 50 PL1; 2017.
96. Pokhrel B, Aiman W, Bhusal K. Thyroid storm. In: StatPearls Treasure Island (FL): StatPearls Publishing; 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK448095/>. [Last updated on 2022 Oct 06].
97. Kumar R, Bansal R, Shergill H, Garg P. Prevalence of thyroid dysfunction in pregnancy and its association with fetomaternal outcomes: A prospective observational study from a tertiary care institute in Northern India. *Clin Epidemiol Glob Health* 2022;19:101201.
98. Indian Thyroid Society. 2019 Recommendations for the Management of Thyroid Dysfunction in Pregnancy. Available from: https://www.indianthyroidsociety.in/assets/img/guidelines/ITS_FOGSI_Recommendations.pdf. [Last accessed on 2025 Feb 07].
99. Indian Thyroid Society in Collaboration with the Endocrine Society in India. Guidelines for Management of Thyroid Dysfunction during Pregnancy. Available from: https://www.indianthyroidsociety.in/assets/img/guidelines/Maternal_Thyroid_Guidelines.pdf. [Last accessed on 2025 Feb 07].
100. Sorah K, Alderson TL. Hyperthyroidism in pregnancy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559203/>. [Last updated on 2023 May 23].
101. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. *Lancet Diabetes Endocrinol* 2013;1:238-49.
102. Iijima S. Pitfalls in the assessment of gestational transient thyrotoxicosis. *Gynecol Endocrinol* 2020;36:662-7.
103. Singh S, Sandhu S. Thyroid disease and pregnancy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538485/>. [Last updated on 2023 Jul 17].
104. Medicines and Healthcare Products Regulatory Agency. Carbimazole: increased risk of congenital malformations; strengthened advice on contraception. Retrieved from: <https://www.gov.uk/drug-safety-update> [Last accessed on 2019 Feb 18].
105. Drugs and Lactation Database (LactMed®) Bethesda (MD): National Institute of Child Health and Human Development; 2006. Methimazole. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501024/>. [Last updated on 2020 Dec 21].
106. Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; 2006. Carbimazole. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501759/>. [Last updated on 2022 Jun 20].